{ "instance": { "adc-20220930.htm adc-20220930_d2.htm": { "axisCustom": 10, "axisStandard": 16, "contextCount": 440, "dts": { "calculationLink": { "local": [ "adc-20220930_cal.xml" ] }, "definitionLink": { "local": [ "adc-20220930_def.xml" ] }, "inline": { "local": [ "adc-20220930.htm", "adc-20220930_d2.htm" ] }, "labelLink": { "local": [ "adc-20220930_lab.xml" ] }, "presentationLink": { "local": [ "adc-20220930_pre.xml" ] }, "schema": { "local": [ "adc-20220930.xsd", "reference-2009-12-16.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 596, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 6, "total": 6 }, "keyCustom": 104, "keyStandard": 198, "memberCustom": 78, "memberStandard": 16, "nsprefix": "adc", "nsuri": "http://adctherapeutics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://adctherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Financial risk management", "role": "http://adctherapeutics.com/role/Financialriskmanagement", "shortName": "Financial risk management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Product revenues, net", "role": "http://adctherapeutics.com/role/Productrevenuesnet", "shortName": "Product revenues, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Segment information", "role": "http://adctherapeutics.com/role/Segmentinformation", "shortName": "Segment information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Operating expense", "role": "http://adctherapeutics.com/role/Operatingexpense", "shortName": "Operating expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Cash and cash equivalents", "role": "http://adctherapeutics.com/role/Cashandcashequivalents", "shortName": "Cash and cash equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Inventories", "role": "http://adctherapeutics.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Intangible assets", "role": "http://adctherapeutics.com/role/Intangibleassets", "shortName": "Intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Non-operating income", "role": "http://adctherapeutics.com/role/Nonoperatingincome", "shortName": "Non-operating income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfJointVenturesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Interest in joint venture", "role": "http://adctherapeutics.com/role/Interestinjointventure", "shortName": "Interest in joint venture", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfJointVenturesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Leases", "role": "http://adctherapeutics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Interim Statement of Operations", "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "shortName": "Condensed Consolidated Interim Statement of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Senior secured term loan facility and warrants", "role": "http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants", "shortName": "Senior secured term loan facility and warrants", "subGroupType": "", "uniqueAnchor": null }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Convertible loans", "role": "http://adctherapeutics.com/role/Convertibleloans", "shortName": "Convertible loans", "subGroupType": "", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Deerfield Warrants", "role": "http://adctherapeutics.com/role/DeerfieldWarrants", "shortName": "Deerfield Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Share-based compensation", "role": "http://adctherapeutics.com/role/Sharebasedcompensation", "shortName": "Share-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Related parties", "role": "http://adctherapeutics.com/role/Relatedparties", "shortName": "Related parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Loss per share", "role": "http://adctherapeutics.com/role/Losspershare", "shortName": "Loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Events after the reporting date", "role": "http://adctherapeutics.com/role/Eventsafterthereportingdate", "shortName": "Events after the reporting date", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DeferredRoyaltyObligationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Deferred royalty obligation", "role": "http://adctherapeutics.com/role/Deferredroyaltyobligation", "shortName": "Deferred royalty obligation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DeferredRoyaltyObligationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Equity", "role": "http://adctherapeutics.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:StatementOfIFRSCompliance", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Significant accounting policies (Policies)", "role": "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies", "shortName": "Significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:StatementOfIFRSCompliance", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Interim Statement of Comprehensive Loss", "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss", "shortName": "Condensed Consolidated Interim Statement of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Basis of preparation (Tables)", "role": "http://adctherapeutics.com/role/BasisofpreparationTables", "shortName": "Basis of preparation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Product revenues, net (Tables)", "role": "http://adctherapeutics.com/role/ProductrevenuesnetTables", "shortName": "Product revenues, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Operating expense (Tables)", "role": "http://adctherapeutics.com/role/OperatingexpenseTables", "shortName": "Operating expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Inventories (Tables)", "role": "http://adctherapeutics.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Intangible assets (Tables)", "role": "http://adctherapeutics.com/role/IntangibleassetsTables", "shortName": "Intangible assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Non-operating income (Tables)", "role": "http://adctherapeutics.com/role/NonoperatingincomeTables", "shortName": "Non-operating income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ifrs-full:DisclosureOfJointVenturesExplanatory", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInterestsInJointArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Interest in joint venture (Tables)", "role": "http://adctherapeutics.com/role/InterestinjointventureTables", "shortName": "Interest in joint venture (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ifrs-full:DisclosureOfJointVenturesExplanatory", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInterestsInJointArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Leases (Tables)", "role": "http://adctherapeutics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Senior secured term loan facility and warrants (Tables)", "role": "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables", "shortName": "Senior secured term loan facility and warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Convertible loans (Tables)", "role": "http://adctherapeutics.com/role/ConvertibleloansTables", "shortName": "Convertible loans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Interim Balance Sheet", "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "shortName": "Condensed Consolidated Interim Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Deerfield Warrants (Tables)", "role": "http://adctherapeutics.com/role/DeerfieldWarrantsTables", "shortName": "Deerfield Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Share-based compensation (Tables)", "role": "http://adctherapeutics.com/role/SharebasedcompensationTables", "shortName": "Share-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Related parties (Tables)", "role": "http://adctherapeutics.com/role/RelatedpartiesTables", "shortName": "Related parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Loss per share (Tables)", "role": "http://adctherapeutics.com/role/LosspershareTables", "shortName": "Loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:NumberOfSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Corporate information (Details)", "role": "http://adctherapeutics.com/role/CorporateinformationDetails", "shortName": "Corporate information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:NumberOfSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "5", "first": true, "lang": "en-US", "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "usdPerGBP", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Basis of preparation - Schedule of Foreign currency exchange rate (Details)", "role": "http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails", "shortName": "Basis of preparation - Schedule of Foreign currency exchange rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "5", "first": true, "lang": "en-US", "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "usdPerGBP", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "adc:DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331", "decimals": "3", "first": true, "lang": "en-US", "name": "adc:PensionObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Basis of preparation - Additional information (Details)", "role": "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails", "shortName": "Basis of preparation - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "adc:DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331", "decimals": "3", "first": true, "lang": "en-US", "name": "adc:PensionObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:ConvertibleNotesSharesConverted", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Significant accounting policies (Details)", "role": "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails", "shortName": "Significant accounting policies (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "iac01c43c0d9347968cf7c0f6d6589b05_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Financial risk management (Details)", "role": "http://adctherapeutics.com/role/FinancialriskmanagementDetails", "shortName": "Financial risk management (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "iac01c43c0d9347968cf7c0f6d6589b05_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "adc:GTNSalesAdjustment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Product revenues, net (Details)", "role": "http://adctherapeutics.com/role/ProductrevenuesnetDetails", "shortName": "Product revenues, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ic28832b49da3403a8b557a594e965059_I20220630", "decimals": "-3", "lang": "en-US", "name": "adc:GTNSalesAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i1a3acb2e8256494bb21952f83d8f6892_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Interim Statement of Changes in Equity", "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "shortName": "Condensed Consolidated Interim Statement of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i1a3acb2e8256494bb21952f83d8f6892_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ib75271c7003f455ea3762473084eeb29_D20220118-20220118", "decimals": "-6", "first": true, "lang": "en-US", "name": "adc:LicenseAgreementMilestonePayments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Product revenues, net - Narrative (Details)", "role": "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails", "shortName": "Product revenues, net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:NumberOfBusinessSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Segment information (Details)", "role": "http://adctherapeutics.com/role/SegmentinformationDetails", "shortName": "Segment information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:NumberOfBusinessSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CostOfSales", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Operating expense - Schedule of Expenses by Nature (Details)", "role": "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails", "shortName": "Operating expense - Schedule of Expenses by Nature (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Operating expense - Narrative (Details)", "role": "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails", "shortName": "Operating expense - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Cash and cash equivalents (Details)", "role": "http://adctherapeutics.com/role/CashandcashequivalentsDetails", "shortName": "Cash and cash equivalents (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:WorkInProgress", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Inventories (Details)", "role": "http://adctherapeutics.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:WorkInProgress", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Inventories - Narrative (Details)", "role": "http://adctherapeutics.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i6f345e8135d943ddb82dfb8c7d312b08_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Intangible assets - Rollforward of Intangible Assets (Details)", "role": "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails", "shortName": "Intangible assets - Rollforward of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "icf2aa78bd37e48d8afb1437f35585633_I20211231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i6898024e6a424206b1716d13c24b930b_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Intangible assets - Narrative (Details)", "role": "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails", "shortName": "Intangible assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i6898024e6a424206b1716d13c24b930b_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Non-operating income - Schedule of Other Income (Expense) (Details)", "role": "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails", "shortName": "Non-operating income - Schedule of Other Income (Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "adc:BorrowingsDeferredFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Interim Statement of Cash Flows", "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "shortName": "Condensed Consolidated Interim Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:AdjustmentsForSharebasedPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:ConvertibleNotesSharesConverted", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Non-operating income - Narrative (Details)", "role": "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "shortName": "Non-operating income - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ifrs-full:DisclosureOfJointVenturesExplanatory", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "adc:DeferredGainOnInvestmentInJointVenture", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Interest in joint venture - Narrative (Details)", "role": "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails", "shortName": "Interest in joint venture - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ifrs-full:DisclosureOfJointVenturesExplanatory", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "adc:DeferredGainOnInvestmentInJointVenture", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Interest in joint venture - Schedule of movement in interest in joint venture (Details)", "role": "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails", "shortName": "Interest in joint venture - Schedule of movement in interest in joint venture (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfJointVenturesExplanatory", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i0eb53627542b4cdba6ba59b049a5b8cc_I20211231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Interest in joint venture - Summary of financial information in joint venture (Details)", "role": "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails", "shortName": "Interest in joint venture - Summary of financial information in joint venture (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory", "ifrs-full:DisclosureOfJointVenturesExplanatory", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i0eb53627542b4cdba6ba59b049a5b8cc_I20211231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "adc:LeaseArea", "reportCount": 1, "unique": true, "unitRef": "sqm", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Leases - Narrative (Details)", "role": "http://adctherapeutics.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "adc:LeaseArea", "reportCount": 1, "unique": true, "unitRef": "sqm", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Leases - Right-of-Use Assets and Accumulated Depreciation (Details)", "role": "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails", "shortName": "Leases - Right-of-Use Assets and Accumulated Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "icf2aa78bd37e48d8afb1437f35585633_I20211231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:DepreciationRightofuseAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Leases - Right-of-Use Asset Depreciation (Details)", "role": "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails", "shortName": "Leases - Right-of-Use Asset Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ie83b9d46aa9540e49e84d64af9846e39_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:DepreciationRightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "adc:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Leases - Schedule of Lease Liabilities (Details)", "role": "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails", "shortName": "Leases - Schedule of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "adc:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i1a3acb2e8256494bb21952f83d8f6892_I20201231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Senior secured term loan facility and warrants - Narrative (Details)", "role": "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "shortName": "Senior secured term loan facility and warrants - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i2b93ddb8d53d4ec2872793932c99d612_I20220815", "decimals": "-5", "lang": "en-US", "name": "adc:BorrowingsFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i552db3596e754dcaac31cd578b8a44be_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Senior secured term loan facility and warrants - Valuation of Derivative (Details)", "role": "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails", "shortName": "Senior secured term loan facility and warrants - Valuation of Derivative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i552db3596e754dcaac31cd578b8a44be_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Corporate information", "role": "http://adctherapeutics.com/role/Corporateinformation", "shortName": "Corporate information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "iea17a01e38b140129bf22b46808b9404_I20220815", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:Borrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Senior secured term loan facility and warrants - Schedule of the First and Second Tranche (Details)", "role": "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails", "shortName": "Senior secured term loan facility and warrants - Schedule of the First and Second Tranche (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "idda45a536b784d9a83b51c5690223542_I20220930", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:Borrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Convertible loans - Narrative (Details)", "role": "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "shortName": "Convertible loans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i82d563da995d45569288f830e5149dfb_I20220815", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:CreditDerivativeFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ic3d81122c2c840e4b693968f8c508748_D20200519-20200519", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:OfferingPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Convertible loans - Valuation of Derivative (Details)", "role": "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "shortName": "Convertible loans - Valuation of Derivative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ic3d81122c2c840e4b693968f8c508748_D20200519-20200519", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:OfferingPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i785f01a211a243bda6e912eb3ec1e0a2_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:InterestExpenseOnBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Convertible loans - Interest Expense (Details)", "role": "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "shortName": "Convertible loans - Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Convertible loans - Change in Fair Value (Details)", "role": "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails", "shortName": "Convertible loans - Change in Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i8541b30e628240598a82d1a6e8ece81c_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i2b93ddb8d53d4ec2872793932c99d612_I20220815", "decimals": "-5", "first": true, "lang": "en-US", "name": "adc:WarrantObligationFairValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Deerfield Warrants - Narrative (Details)", "role": "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "shortName": "Deerfield Warrants - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ia26abd4a41954e9e9346a99a9f049985_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Deerfield Warrants - Schedule of Valuation Inputs (Details)", "role": "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "shortName": "Deerfield Warrants - Schedule of Valuation Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ia26abd4a41954e9e9346a99a9f049985_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Share-based compensation - Narrative (Details)", "role": "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "shortName": "Share-based compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ic28832b49da3403a8b557a594e965059_I20220630", "decimals": "INF", "lang": "en-US", "name": "ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Share-based compensation - Schedule of Number of Awards Outstanding and Weighted Average Strike Price (Details)", "role": "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails", "shortName": "Share-based compensation - Schedule of Number of Awards Outstanding and Weighted Average Strike Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": "2", "lang": "en-US", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ExpectedDividendShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Share-based compensation expense - Schedule of Fair Value Assumptions For Options Granted (Details)", "role": "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails", "shortName": "Share-based compensation expense - Schedule of Fair Value Assumptions For Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ExpectedDividendShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Basis of preparation", "role": "http://adctherapeutics.com/role/Basisofpreparation", "shortName": "Basis of preparation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i1eb06d614e3447ffb6c90235d957a286_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Share-based compensation - Schedule of Other Equity Instruments Outstanding (Details)", "role": "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails", "shortName": "Share-based compensation - Schedule of Other Equity Instruments Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i1eb06d614e3447ffb6c90235d957a286_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Share-based compensation - Schedule of Share-based Compensation Reserve (Details)", "role": "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails", "shortName": "Share-based compensation - Schedule of Share-based Compensation Reserve (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if6b8e02492be4003ab27ad39ebc0924a_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:NumberOfSubsidiariesProvideServicesTo", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Related parties - Narrative (Details)", "role": "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails", "shortName": "Related parties - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:NumberOfSubsidiariesProvideServicesTo", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Related parties - Schedule of Key Management Compensation (Details)", "role": "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails", "shortName": "Related parties - Schedule of Key Management Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Loss per share (Details)", "role": "http://adctherapeutics.com/role/LosspershareDetails", "shortName": "Loss per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "0", "lang": "en-US", "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Loss per share -Schedule of Potentially Dilutive Securities (Details)", "role": "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails", "shortName": "Loss per share -Schedule of Potentially Dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ib75271c7003f455ea3762473084eeb29_D20220118-20220118", "decimals": "-6", "first": true, "lang": "en-US", "name": "adc:ProceedsFromLicenseAgreement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Events after the reporting date (Details)", "role": "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "shortName": "Events after the reporting date (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ie7216894bf0e483e85c7a8417528b234_I20210825", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:RoyaltyPurchaseAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Deferred royalty obligation (Details)", "role": "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails", "shortName": "Deferred royalty obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "ie7216894bf0e483e85c7a8417528b234_I20210825", "decimals": "INF", "first": true, "lang": "en-US", "name": "adc:RoyaltyPurchaseAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "adc:IssueOfEquityThroughExchangeAgreement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Equity (Details)", "role": "http://adctherapeutics.com/role/EquityDetails", "shortName": "Equity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Significant accounting policies", "role": "http://adctherapeutics.com/role/Significantaccountingpolicies", "shortName": "Significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adc-20220930_d2.htm", "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 99, "tag": { "adc_A2019EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Equity Incentive Plan", "label": "2019 Equity Incentive Plan [Member]", "terseLabel": "2019 Equity Incentive Plan" } } }, "localname": "A2019EquityIncentivePlanMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "domainItemType" }, "adc_A2019EquityIncentivePlanRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Equity Incentive Plan - RSUs", "label": "2019 Equity Incentive Plan - RSUs [Member]", "terseLabel": "Equity Incentive Plan 2019 - RSUs" } } }, "localname": "A2019EquityIncentivePlanRSUsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adc_A2019EquityIncentivePlanShareOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Equity Incentive Plan - Share Options", "label": "2019 Equity Incentive Plan - Share Options [Member]", "terseLabel": "Equity Incentive Plan 2019 - Share Options" } } }, "localname": "A2019EquityIncentivePlanShareOptionsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adc_A2022ESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 ESPP", "label": "2022 ESPP [Member]", "terseLabel": "2022 ESPP" } } }, "localname": "A2022ESPPMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]", "label": "Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]", "terseLabel": "Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]" } } }, "localname": "AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Payable, Deferred Royalty Obligation Transaction Costs", "label": "Accounts Payable, Deferred Royalty Obligation Transaction Costs", "terseLabel": "Deferred royalty obligation transaction costs recorded in Accounts payable" } } }, "localname": "AccountsPayableDeferredRoyaltyObligationTransactionCosts", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_AccruedShareBasedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Share Based Compensation", "label": "Accrued Share Based Compensation", "terseLabel": "Accrued Share Based Compensation" } } }, "localname": "AccruedShareBasedCompensation", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_AdditionsToLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions To Lease Liabilities", "label": "Additions To Lease Liabilities", "terseLabel": "Additions" } } }, "localname": "AdditionsToLeaseLiabilities", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments For Depreciation Expense Of Right-Of-Use Assets", "label": "Adjustments For Depreciation Expense Of Right-Of-Use Assets", "terseLabel": "Depreciation of right-of-use assets" } } }, "localname": "AdjustmentsForDepreciationExpenseOfRightOfUseAssets", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments For Depreciation Expense, Property, Plant And Equipment", "label": "Adjustments For Depreciation Expense, Property, Plant And Equipment", "terseLabel": "Depreciation of property, plant and equipment" } } }, "localname": "AdjustmentsForDepreciationExpensePropertyPlantAndEquipment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 15.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments For Gains (Losses) On change In Fair Value Of Warrants", "label": "Adjustments For Gains (Losses) On change In Fair Value Of Warrants", "negatedTerseLabel": "Warrant obligations, decrease in fair value" } } }, "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments For Increase (Decrease) In Non-Current Net Defined Benefit Liability", "label": "Adjustments For Increase (Decrease) In Non-Current Net Defined Benefit Liability", "terseLabel": "Change in defined benefit pension liability" } } }, "localname": "AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_AfterFirstFiveYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "After First Five Years", "label": "After First Five Years [Member]", "terseLabel": "After First Five Years" } } }, "localname": "AfterFirstFiveYearsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_AmountsDueFromRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts Due From Related Parties", "label": "Amounts Due From Related Parties", "terseLabel": "Amounts due from related parties" } } }, "localname": "AmountsDueFromRelatedParties", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_AnnualEquityAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual Equity Award", "label": "Annual Equity Award [Member]", "terseLabel": "Annual Equity Award" } } }, "localname": "AnnualEquityAwardMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_ApplicationApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Application Approval", "label": "Application Approval [Member]", "terseLabel": "Application Approval" } } }, "localname": "ApplicationApprovalMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_AuvenTherapeuticsHoldingsLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Auven Therapeutics Holdings, L.P.", "label": "Auven Therapeutics Holdings, L.P. [Member]", "terseLabel": "Auven Therapeutics Holdings, L.P." } } }, "localname": "AuvenTherapeuticsHoldingsLPMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Base Rate", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_BlackScholesValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Black-Scholes Value", "label": "Black-Scholes Value [Member]", "terseLabel": "Black-Scholes Value" } } }, "localname": "BlackScholesValueMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_BorrowingConversionPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing Conversion Period", "label": "Borrowing Conversion Period [Domain]", "terseLabel": "Borrowing Conversion Period [Domain]" } } }, "localname": "BorrowingConversionPeriodDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing Facilities, Conversion Price Per Share, Percentage Of IPO Share Price", "label": "Borrowing Facilities, Conversion Price Per Share, Percentage Of IPO Share Price", "terseLabel": "Conversion percentage" } } }, "localname": "BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" ], "xbrltype": "percentItemType" }, "adc_BorrowingFacilitiesMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Borrowing Facilities, Maximum Borrowing Capacity", "label": "Borrowing Facilities, Maximum Borrowing Capacity", "terseLabel": "Borrowings, maximum borrowing capacity" } } }, "localname": "BorrowingFacilitiesMaximumBorrowingCapacity", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "adc_BorrowingNumberOfComponents": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing, Number Of Components", "label": "Borrowing, Number Of Components", "terseLabel": "Number of borrowing components" } } }, "localname": "BorrowingNumberOfComponents", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "integerItemType" }, "adc_BorrowingPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing Period", "label": "Borrowing Period [Axis]", "terseLabel": "Borrowing Period [Axis]" } } }, "localname": "BorrowingPeriodAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "stringItemType" }, "adc_BorrowingPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing Period [Domain]", "label": "Borrowing Period [Domain]", "terseLabel": "Borrowing Period [Domain]" } } }, "localname": "BorrowingPeriodDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_BorrowingsConversionPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings Conversion Period", "label": "Borrowings Conversion Period [Axis]", "terseLabel": "Borrowings Conversion Period [Axis]" } } }, "localname": "BorrowingsConversionPeriodAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "adc_BorrowingsConversionPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings Conversion Period One", "label": "Borrowings Conversion Period One [Member]", "terseLabel": "Conversion period one" } } }, "localname": "BorrowingsConversionPeriodOneMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents", "label": "Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents", "terseLabel": "Cash and cash equivalents, minimum quarterly balance" } } }, "localname": "BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CashandcashequivalentsDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_BorrowingsDeferredFinancingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Borrowings, Deferred Financing Costs", "label": "Borrowings, Deferred Financing Costs", "terseLabel": "Convertible loans, derivatives, transaction costs" } } }, "localname": "BorrowingsDeferredFinancingCosts", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "adc_BorrowingsFacilitiesExitFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings Facilities, Exit Fee, Percentage", "label": "Borrowings Facilities, Exit Fee, Percentage", "terseLabel": "Exit fee" } } }, "localname": "BorrowingsFacilitiesExitFeePercentage", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "percentItemType" }, "adc_BorrowingsFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Borrowings, Fair Value", "label": "Borrowings, Fair Value", "terseLabel": "Borrowings, Fair Value" } } }, "localname": "BorrowingsFairValue", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_BorrowingsImpliedEffectiveInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings, Implied Effective Interest Rate", "label": "Borrowings, Implied Effective Interest Rate", "terseLabel": "Implied effective interest rate" } } }, "localname": "BorrowingsImpliedEffectiveInterestRate", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "percentItemType" }, "adc_CamiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cami", "label": "Cami [Member]", "terseLabel": "Cami" } } }, "localname": "CamiMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Capital Expenditures, Incurred But Not Yet Paid", "label": "Capital Expenditures, Incurred But Not Yet Paid", "terseLabel": "Capital expenditures and intangible asset acquisitions recorded in Accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_ConsolidatedStatementOfFinancialPositionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated Statement of Financial Position [Line Items]", "label": "Consolidated Statement of Financial Position [Line Items]", "terseLabel": "Consolidated Statement of Financial Position [Line Items]" } } }, "localname": "ConsolidatedStatementOfFinancialPositionLineItems", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "adc_ConsolidatedStatementOfFinancialPositionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated Statement of Financial Position [Table]", "label": "Consolidated Statement of Financial Position [Table]", "terseLabel": "Consolidated Statement of Financial Position [Table]" } } }, "localname": "ConsolidatedStatementOfFinancialPositionTable", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "adc_ConversionPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Period Two", "label": "Conversion Period Two [Member]", "terseLabel": "Conversion period two" } } }, "localname": "ConversionPeriodTwoMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_ConvertibleLoansContingentlyIssuableSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Loans, Contingently Issuable Shares", "label": "Convertible Loans, Contingently Issuable Shares [Member]", "terseLabel": "Conversion of the principal amount of convertible loans into the Company\u2019s common shares" } } }, "localname": "ConvertibleLoansContingentlyIssuableSharesMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adc_ConvertibleLoansExchange": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible Loans Exchange", "label": "Convertible Loans Exchange", "negatedTerseLabel": "Convertible loans exchange" } } }, "localname": "ConvertibleLoansExchange", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_ConvertibleLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Loans", "label": "Convertible Loans [Member]", "terseLabel": "Convertible Loans" } } }, "localname": "ConvertibleLoansMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "domainItemType" }, "adc_ConvertibleNotesSharesConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes, Shares Converted", "label": "Convertible Notes, Shares Converted", "terseLabel": "Convertible Notes, Shares Converted" } } }, "localname": "ConvertibleNotesSharesConverted", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/EquityDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "sharesItemType" }, "adc_ConvertibleNotesValueConverted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible Notes, Value Converted", "label": "Convertible Notes, Value Converted", "terseLabel": "Convertible Notes, Value Converted" } } }, "localname": "ConvertibleNotesValueConverted", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails" ], "xbrltype": "monetaryItemType" }, "adc_CorporateInformationAndStatementOfIFRSComplianceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate Information And Statement Of IFRS Compliance [Abstract]", "label": "Corporate Information And Statement Of IFRS Compliance [Abstract]", "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]" } } }, "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current Accrued Expenses And Other Current Liabilities, Sales Adjustment", "label": "Current Accrued Expenses And Other Current Liabilities, Sales Adjustment", "terseLabel": "Other current liabilities" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetDetails" ], "xbrltype": "monetaryItemType" }, "adc_CurrentFinishedGoodsHeldOnConsignment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current Finished Goods Held On Consignment", "label": "Current Finished Goods Held On Consignment", "terseLabel": "Current Finished Goods Held On Consignment" } } }, "localname": "CurrentFinishedGoodsHeldOnConsignment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "adc_DeerfieldWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deerfield Warrants", "label": "Deerfield Warrants [Member]", "terseLabel": "Deerfield Warrants" } } }, "localname": "DeerfieldWarrantsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails" ], "xbrltype": "domainItemType" }, "adc_DeferredFinancingCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Financing Costs", "label": "Deferred Financing Costs [Member]", "terseLabel": "Transaction costs" } } }, "localname": "DeferredFinancingCostsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" ], "xbrltype": "domainItemType" }, "adc_DeferredGainOnInvestmentInJointVenture": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Gain On Investment In Joint Venture", "label": "Deferred Gain On Investment In Joint Venture", "terseLabel": "Deferred Gain On Investment In Joint Venture" } } }, "localname": "DeferredGainOnInvestmentInJointVenture", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_DeferredRoyaltyObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Royalty Obligation", "label": "Deferred Royalty Obligation", "terseLabel": "Deferred Royalty Obligation" } } }, "localname": "DeferredRoyaltyObligation", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_DeferredRoyaltyObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Royalty Obligation [Abstract]", "label": "Deferred Royalty Obligation [Abstract]" } } }, "localname": "DeferredRoyaltyObligationAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_DeferredRoyaltyObligationNoncurrent": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 7.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Royalty Obligation, Noncurrent", "label": "Deferred Royalty Obligation, Noncurrent", "terseLabel": "Deferred royalty obligation, long-term" } } }, "localname": "DeferredRoyaltyObligationNoncurrent", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "adc_DeferredRoyaltyObligationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Royalty Obligation", "label": "Deferred Royalty Obligation [Text Block]", "terseLabel": "Deferred royalty obligation" } } }, "localname": "DeferredRoyaltyObligationTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/Deferredroyaltyobligation" ], "xbrltype": "textBlockItemType" }, "adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description Of Accounting Policy For Other Income (Expense) Explanatory", "label": "Description Of Accounting Policy For Other Income (Expense) Explanatory [Policy Text Block]", "terseLabel": "Description Of Accounting Policy For Other Income (Expense) Explanatory" } } }, "localname": "DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description Of Accounting Policy For Selling And Marketing Expenses Explanatory", "label": "Description Of Accounting Policy For Selling And Marketing Expenses Explanatory [Policy Text Block]", "terseLabel": "Selling and marketing (\"S&M\") expenses" } } }, "localname": "DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description Of Accounting Policy For Use Of Estimates And Judgements Explanatory", "label": "Description Of Accounting Policy For Use Of Estimates And Judgements Explanatory [Policy Text Block]", "terseLabel": "Use of estimates and judgements" } } }, "localname": "DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detailed Information About Foreign Currency Exchange Rate Explanatory", "label": "Detailed Information About Foreign Currency Exchange Rate Explanatory [Table Text Block]", "terseLabel": "Schedule of Foreign currency exchange rate" } } }, "localname": "DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationTables" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Expenses By Nature Explanatory", "label": "Disclosure Of Detailed Information About Expenses By Nature Explanatory [Table Text Block]", "terseLabel": "Disclosure Of Detailed Information About Expenses By Nature Explanatory" } } }, "localname": "DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseTables" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Expenses By Nature", "label": "Disclosure Of Detailed Information About Expenses By Nature [Line Items]", "terseLabel": "Disclosure Of Detailed Information About Expenses By Nature [Line Items]" } } }, "localname": "DisclosureOfDetailedInformationAboutExpensesByNatureLineItems", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InventoriesNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "stringItemType" }, "adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Expenses By Nature [Table]", "label": "Disclosure Of Detailed Information About Expenses By Nature [Table]", "terseLabel": "Disclosure Of Detailed Information About Expenses By Nature [Table]" } } }, "localname": "DisclosureOfDetailedInformationAboutExpensesByNatureTable", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InventoriesNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "stringItemType" }, "adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Lease Liabilities [Table]", "label": "Disclosure Of Detailed Information About Lease Liabilities [Table]", "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Table]" } } }, "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Other Income (Expense) Explanatory", "label": "Disclosure Of Detailed Information About Other Income (Expense) Explanatory [Table Text Block]", "terseLabel": "Schedule of Other income (expense)" } } }, "localname": "DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/NonoperatingincomeTables" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets", "label": "Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets [Table Text Block]", "terseLabel": "Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets" } } }, "localname": "DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetTables" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Sales Adjustments Explanatory", "label": "Disclosure Of Detailed Information About Sales Adjustments Explanatory [Table Text Block]", "terseLabel": "Disclosure Of Detailed Information About Sales Adjustments Explanatory" } } }, "localname": "DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetTables" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Share-based Compensation Reserve Explanatory", "label": "Disclosure Of Detailed Information About Share-based Compensation Reserve Explanatory [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation Reserve" } } }, "localname": "DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Inventory Information Explanatory", "label": "Disclosure Of Inventory Information Explanatory [Table Text Block]", "terseLabel": "Disclosure Of Inventory Information Explanatory" } } }, "localname": "DisclosureOfInventoryInformationExplanatoryTableTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Other Non-Operating Income, Explanatory", "label": "Disclosure Of Other Non-Operating Income, Explanatory [Text Block]", "terseLabel": "Non-operating income" } } }, "localname": "DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/Nonoperatingincome" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Quantitative Information About Lease Liabilities", "label": "Disclosure Of Quantitative Information About Lease Liabilities [Line Items]", "terseLabel": "Disclosure Of Quantitative Information About Lease Liabilities [Line Items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Quantitative Information About Lease Liabilities", "label": "Disclosure Of Quantitative Information About Lease Liabilities [Table Text Block]", "terseLabel": "Schedule of quantitative information about lease liabilities" } } }, "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "adc_DisclosureOfWarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Warrants", "label": "Disclosure Of Warrants [Text Block]", "terseLabel": "Deerfield Warrants" } } }, "localname": "DisclosureOfWarrantsTextBlock", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeerfieldWarrants" ], "xbrltype": "textBlockItemType" }, "adc_DividendYieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividend Yield", "label": "Dividend Yield [Member]", "terseLabel": "Dividend Yield [Member]" } } }, "localname": "DividendYieldMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_DosingOfSpecificNumberOfPatientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dosing Of Specific Number Of Patients", "label": "Dosing Of Specific Number Of Patients [Member]", "terseLabel": "Dosing Of Specific Number Of Patients" } } }, "localname": "DosingOfSpecificNumberOfPatientsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_EmployeeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Expenses", "label": "Employee Expenses [Member]", "terseLabel": "Employee expense" } } }, "localname": "EmployeeExpensesMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "domainItemType" }, "adc_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Option", "label": "Employee Stock Option [Member]", "terseLabel": "Share Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "domainItemType" }, "adc_EventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Events After Reporting Period [Abstract]", "label": "Events After Reporting Period [Abstract]" } } }, "localname": "EventsAfterReportingPeriodAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_ExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Agreement", "label": "Exchange Agreement [Member]", "terseLabel": "Exchange Agreement" } } }, "localname": "ExchangeAgreementMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "adc_ExchangeOfConvertibleNotesForWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exchange Of Convertible Notes For Warrants", "label": "Exchange Of Convertible Notes For Warrants", "terseLabel": "Exchange Of Convertible Notes For Warrants" } } }, "localname": "ExchangeOfConvertibleNotesForWarrants", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails" ], "xbrltype": "monetaryItemType" }, "adc_ExecutiveCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive Compensation", "label": "Executive Compensation [Member]", "terseLabel": "Executive Compensation" } } }, "localname": "ExecutiveCompensationMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_ExercisePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price", "label": "Exercise Price [Member]", "terseLabel": "Exercise Price" } } }, "localname": "ExercisePriceMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails" ], "xbrltype": "domainItemType" }, "adc_ExpectedTermMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected Term", "label": "Expected Term [Member]", "terseLabel": "Expected Term" } } }, "localname": "ExpectedTermMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_ExpectedVolatilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected Volatility", "label": "Expected Volatility [Member]", "terseLabel": "Expected Volatility" } } }, "localname": "ExpectedVolatilityMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_ExpensesByNatureAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expenses By Nature", "label": "Expenses By Nature [Axis]", "terseLabel": "Expenses By Nature [Axis]" } } }, "localname": "ExpensesByNatureAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "stringItemType" }, "adc_ExpensesByNatureDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expenses By Nature [Domain]", "label": "Expenses By Nature [Domain]", "terseLabel": "Expenses By Nature [Domain]" } } }, "localname": "ExpensesByNatureDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "domainItemType" }, "adc_ExpensesByNatureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expenses By Nature", "label": "Expenses By Nature [Member]", "terseLabel": "Expenses By Nature" } } }, "localname": "ExpensesByNatureMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "domainItemType" }, "adc_ExternalCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "External Costs", "label": "External Costs [Member]", "terseLabel": "External costs" } } }, "localname": "ExternalCostsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "domainItemType" }, "adc_FacilityAgreementWithDeerfieldPartnersLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility Agreement with Deerfield Partners, L.P.", "label": "Facility Agreement with Deerfield Partners, L.P. [Member]", "terseLabel": "Facility Agreement with Deerfield Partners, L.P." } } }, "localname": "FacilityAgreementWithDeerfieldPartnersLPMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility Agreement With Deerfield Partners, L.P., Tranche One", "label": "Facility Agreement With Deerfield Partners, L.P., Tranche One [Member]", "terseLabel": "Facility Agreement With Deerfield Partners, L.P., Tranche One" } } }, "localname": "FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails", "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval", "label": "Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval [Member]", "terseLabel": "Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval" } } }, "localname": "FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails" ], "xbrltype": "domainItemType" }, "adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility Agreement With Deerfield Partners, L.P., Tranche Two", "label": "Facility Agreement With Deerfield Partners, L.P., Tranche Two [Member]", "terseLabel": "Facility Agreement With Deerfield Partners, L.P., Tranche Two" } } }, "localname": "FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails", "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval", "label": "Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval [Member]", "terseLabel": "Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval" } } }, "localname": "FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails" ], "xbrltype": "domainItemType" }, "adc_FinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Instruments [Abstract]", "label": "Financial Instruments [Abstract]", "terseLabel": "Financial Instruments [Abstract]" } } }, "localname": "FinancialInstrumentsAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_FirstFiveYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Five Years", "label": "First Five Years [Member]", "terseLabel": "First Five Years" } } }, "localname": "FirstFiveYearsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_FirstInvestmentAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Investment Amount", "label": "First Investment Amount [Member]", "terseLabel": "First Investment Amount" } } }, "localname": "FirstInvestmentAmountMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Follow-On Transaction Costs, Accounts Payable And Other Current Liabilities", "label": "Follow-On Transaction Costs, Accounts Payable And Other Current Liabilities", "terseLabel": "Follow-on transaction costs recorded in Accounts payable and Other current liabilities" } } }, "localname": "FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_ForcedConversionPriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forced Conversion Price", "label": "Forced Conversion Price [Member]", "terseLabel": "Forced Conversion Price (in USD per share)" } } }, "localname": "ForcedConversionPriceMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails" ], "xbrltype": "domainItemType" }, "adc_GTNSalesAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "GTN Sales Adjustment", "label": "GTN Sales Adjustment", "periodEndLabel": "Sales adjustment, ending balance", "terseLabel": "Sales adjustment, beginning balance" } } }, "localname": "GTNSalesAdjustment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetDetails" ], "xbrltype": "monetaryItemType" }, "adc_GTNSalesAdjustmentCreditsAndPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "GTN Sales Adjustment, Credits And Payments", "label": "GTN Sales Adjustment, Credits And Payments", "terseLabel": "GTN Sales Adjustment, Credits And Payments" } } }, "localname": "GTNSalesAdjustmentCreditsAndPayments", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetDetails" ], "xbrltype": "monetaryItemType" }, "adc_GTNSalesAdjustmentProvision": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "GTN Sales Adjustment, Provision", "label": "GTN Sales Adjustment, Provision", "terseLabel": "GTN Sales Adjustment, Provision" } } }, "localname": "GTNSalesAdjustmentProvision", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetDetails" ], "xbrltype": "monetaryItemType" }, "adc_GTNSalesAdjustmentProvisionPriorPeriodSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "GTN Sales Adjustment, Provision, Prior Period Sales", "label": "GTN Sales Adjustment, Provision, Prior Period Sales", "terseLabel": "GTN Sales Adjustment, Provision, Prior Period Sales" } } }, "localname": "GTNSalesAdjustmentProvisionPriorPeriodSales", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetDetails" ], "xbrltype": "monetaryItemType" }, "adc_GainsLossOnChangeInFairValueWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains (Loss) On Change In Fair Value, Warrants", "label": "Gains (Loss) On Change In Fair Value, Warrants", "terseLabel": "Deerfield warrant obligation, change in fair value income" } } }, "localname": "GainsLossOnChangeInFairValueWarrants", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "adc_GainsLossOnExtinguishmentOfBorrowings": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 14.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains (Loss) On Extinguishment Of Borrowings", "label": "Gains (Loss) On Extinguishment Of Borrowings", "terseLabel": "Loss on extinguishment" } } }, "localname": "GainsLossOnExtinguishmentOfBorrowings", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "http://adctherapeutics.com/role/EquityDetails", "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "adc_GeneralAndAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General And Administrative Expense", "label": "General And Administrative Expense [Member]", "terseLabel": "G&A expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails" ], "xbrltype": "domainItemType" }, "adc_ImpliedBondYieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Implied Bond Yield", "label": "Implied Bond Yield [Member]", "terseLabel": "Implied Bond Yield [Member]" } } }, "localname": "ImpliedBondYieldMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_IncentivePlan2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Plan 2014", "label": "Incentive Plan 2014 [Member]", "terseLabel": "Incentive Plan 2014 [Member]" } } }, "localname": "IncentivePlan2014Member", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "domainItemType" }, "adc_IncomeStatementLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Statement Location", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails" ], "xbrltype": "stringItemType" }, "adc_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Statement Location", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Member]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails" ], "xbrltype": "domainItemType" }, "adc_IncreaseDecreaseInReserveOfShareBasedPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Reserve Of Share-Based Payments", "label": "Increase (Decrease) In Reserve Of Share-Based Payments", "terseLabel": "Increase in reserve of share-based payments" } } }, "localname": "IncreaseDecreaseInReserveOfShareBasedPayments", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "monetaryItemType" }, "adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Reserve Of Share-Based Payments, Tax And Social Charge Deductions", "label": "Increase (Decrease) In Reserve Of Share-Based Payments, Tax And Social Charge Deductions", "terseLabel": "Tax expense from share-based payment transactions with employees" } } }, "localname": "IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "monetaryItemType" }, "adc_IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 5.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "localname": "IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "monetaryItemType" }, "adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Through Modification Of Lease Terms, Lease Liabilities", "label": "Increase (Decrease) Through Modification Of Lease Terms, Lease Liabilities", "terseLabel": "Modification of lease terms" } } }, "localname": "IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Through Modification Of Lease Terms, Right-Of-Use Assets", "label": "Increase (Decrease) Through Modification Of Lease Terms, Right-Of-Use Assets", "negatedTerseLabel": "Lease termination" } } }, "localname": "IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Through Net Exchange Differences, Lease Liabilities", "label": "Increase (Decrease) Through Net Exchange Differences, Lease Liabilities", "terseLabel": "Exchange difference" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Through Net Exchange Differences, Right-Of-Use Assets", "label": "Increase (Decrease) Through Net Exchange Differences, Right-Of-Use Assets", "terseLabel": "Exchange difference" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "adc_IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "localname": "IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "monetaryItemType" }, "adc_InitialPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering", "label": "Initial Public Offering [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share", "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share", "terseLabel": "Potentially dilutive securities" } } }, "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share", "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]", "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]", "terseLabel": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]" } } }, "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share", "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Member]", "terseLabel": "Antidilutive Securities" } } }, "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adc_IntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets [Abstract]", "label": "Intangible Assets [Abstract]", "terseLabel": "Intangible Assets [Abstract]" } } }, "localname": "IntangibleAssetsAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_InterestsInOtherEntitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interests In Other Entities [Abstract]", "label": "Interests In Other Entities [Abstract]" } } }, "localname": "InterestsInOtherEntitiesAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_InternalDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internal Development Costs", "label": "Internal Development Costs [Member]", "terseLabel": "Internal development costs" } } }, "localname": "InternalDevelopmentCostsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "adc_InventoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory [Abstract]", "label": "Inventory [Abstract]", "terseLabel": "Inventory [Abstract]" } } }, "localname": "InventoryAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_InventoryAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "InventoryAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InventoriesNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" ], "xbrltype": "stringItemType" }, "adc_InventoryDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory [Domain]", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "InventoryDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InventoriesNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_IssuanceOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance Of Shares", "label": "Issuance Of Shares", "terseLabel": "Issuance of shares, Deerfield exchange agreement" } } }, "localname": "IssuanceOfShares", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_IssueOfEquityThroughCapitalizationOfReserves": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 4.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "localname": "IssueOfEquityThroughCapitalizationOfReserves", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "monetaryItemType" }, "adc_IssueOfEquityThroughExchangeAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issue Of Equity Through Exchange Agreement", "label": "Issue Of Equity Through Exchange Agreement", "terseLabel": "Issuance of shares, Deerfield exchange agreement, net of transaction costs" } } }, "localname": "IssueOfEquityThroughExchangeAgreement", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "adc_IssueOfEquityThroughFollowOnOffering": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 6.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "localname": "IssueOfEquityThroughFollowOnOffering", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "monetaryItemType" }, "adc_IssueOfEquityThroughInitialPublicOffering": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "localname": "IssueOfEquityThroughInitialPublicOffering", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "monetaryItemType" }, "adc_IssueOfEquityThroughOverAllotmentOption": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 8.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "localname": "IssueOfEquityThroughOverAllotmentOption", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "monetaryItemType" }, "adc_IssueOfEquityThroughPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issue Of Equity Through Purchase Agreement", "label": "Issue Of Equity Through Purchase Agreement", "terseLabel": "Issuance of shares, share purchase agreement, net of transaction costs" } } }, "localname": "IssueOfEquityThroughPurchaseAgreement", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "adc_LeaseArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Area", "label": "Lease Area", "terseLabel": "Lease area (in square meters)" } } }, "localname": "LeaseArea", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "adc_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_LicenseAgreementCappedContribution": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Capped Contribution", "label": "License Agreement, Capped Contribution", "terseLabel": "License Agreement, Capped Contribution" } } }, "localname": "LicenseAgreementCappedContribution", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_LicenseAgreementMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Milestone Payments", "label": "License Agreement, Milestone Payments", "terseLabel": "License Agreement, Milestone Payments" } } }, "localname": "LicenseAgreementMilestonePayments", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_LicenseAgreementPercentOfClinicalTrialCostsPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Percent Of Clinical Trial Costs Paid", "label": "License Agreement, Percent Of Clinical Trial Costs Paid", "terseLabel": "License Agreement, Percent Of Clinical Trial Costs Paid" } } }, "localname": "LicenseAgreementPercentOfClinicalTrialCostsPaid", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "percentItemType" }, "adc_LicensePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Payment", "label": "License Payment [Member]", "terseLabel": "License Payment" } } }, "localname": "LicensePaymentMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_LicenseRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Revenue", "label": "License Revenue [Member]", "terseLabel": "License revenue" } } }, "localname": "LicenseRevenueMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "domainItemType" }, "adc_LicenseToAcquireAnAntibodyZYNLONTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License To Acquire An Antibody, ZYNLONTA", "label": "License To Acquire An Antibody, ZYNLONTA [Member]", "terseLabel": "License To Acquire An Antibody, ZYNLONTA" } } }, "localname": "LicenseToAcquireAnAntibodyZYNLONTAMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2)", "label": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2) [Member]", "terseLabel": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2)" } } }, "localname": "LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA", "label": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA [Member]", "terseLabel": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA" } } }, "localname": "LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_LicensesDefiniteLivedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licenses, Definite-Lived", "label": "Licenses, Definite-Lived [Member]", "terseLabel": "Licenses" } } }, "localname": "LicensesDefiniteLivedMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "adc_LicensesIndefiniteLivedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licenses, Indefinite-Lived", "label": "Licenses, Indefinite-Lived [Member]", "terseLabel": "Licenses" } } }, "localname": "LicensesIndefiniteLivedMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "adc_LoanAgreementFirstTrancheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Agreement, First Tranche", "label": "Loan Agreement, First Tranche [Member]", "terseLabel": "Loan Agreement, First Tranche" } } }, "localname": "LoanAgreementFirstTrancheMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CorporateinformationDetails" ], "xbrltype": "domainItemType" }, "adc_LoanAgreementFutureTranchesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Agreement, Future Tranches", "label": "Loan Agreement, Future Tranches [Member]", "terseLabel": "Loan Agreement, Future Tranches" } } }, "localname": "LoanAgreementFutureTranchesMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CorporateinformationDetails" ], "xbrltype": "domainItemType" }, "adc_LoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Agreement", "label": "Loan Agreement [Member]", "terseLabel": "Loan Agreement" } } }, "localname": "LoanAgreementMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_ManufacturingOfAntibodiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing Of Antibodies", "label": "Manufacturing Of Antibodies [Member]", "terseLabel": "Manufacturing Of Antibodies" } } }, "localname": "ManufacturingOfAntibodiesMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum Term Of Options Granted For Share-Based Payment Arrangement", "label": "Maximum Term Of Options Granted For Share-Based Payment Arrangement", "terseLabel": "Contractual term" } } }, "localname": "MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "adc_MilestonePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment", "label": "Milestone Payment [Member]", "terseLabel": "Milestone Payment" } } }, "localname": "MilestonePaymentMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_NetCarryingAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Carrying Amount", "label": "Net Carrying Amount [Member]", "terseLabel": "Net Carrying Amount" } } }, "localname": "NetCarryingAmountMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" ], "xbrltype": "domainItemType" }, "adc_NonOperatingIncomeExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-Operating Income (Expense)", "label": "Non-Operating Income (Expense)", "terseLabel": "Non-operating income (expense)" } } }, "localname": "NonOperatingIncomeExpense", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "adc_NumberOfBusinessSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Business Segments", "label": "Number Of Business Segments", "terseLabel": "Number of business segments" } } }, "localname": "NumberOfBusinessSegments", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SegmentinformationDetails" ], "xbrltype": "integerItemType" }, "adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Product Candidates Developed And Commercialized In Joint Venture", "label": "Number Of Product Candidates Developed And Commercialized In Joint Venture", "terseLabel": "Number of product candidates developed and commercialized in joint venture" } } }, "localname": "NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails" ], "xbrltype": "integerItemType" }, "adc_NumberOfProductsDevelopedAndCommercializedInJointVenture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Products Developed And Commercialized In Joint Venture", "label": "Number Of Products Developed And Commercialized In Joint Venture", "terseLabel": "Number of products developed and commercialized in joint venture" } } }, "localname": "NumberOfProductsDevelopedAndCommercializedInJointVenture", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails" ], "xbrltype": "integerItemType" }, "adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Share Options Vested And Exercisable In Share-Based Payment Arrangement", "label": "Number Of Share Options Vested And Exercisable In Share-Based Payment Arrangement", "terseLabel": "Awards vested and exercisable (in shares)" } } }, "localname": "NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "adc_NumberOfSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Subsidiaries", "label": "Number Of Subsidiaries", "terseLabel": "Number of subsidiaries" } } }, "localname": "NumberOfSubsidiaries", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CorporateinformationDetails" ], "xbrltype": "integerItemType" }, "adc_NumberOfSubsidiariesProvideServicesTo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Subsidiaries Provide Services To", "label": "Number Of Subsidiaries Provide Services To", "terseLabel": "Number of subsidiaries provide services to" } } }, "localname": "NumberOfSubsidiariesProvideServicesTo", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "adc_OakTreeAndOwlRockWarrantObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oak Tree And Owl Rock Warrant Obligations", "label": "Oak Tree And Owl Rock Warrant Obligations [Member]", "terseLabel": "Oak Tree And Owl Rock Warrant Obligations" } } }, "localname": "OakTreeAndOwlRockWarrantObligationsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_OfferingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering Price Per Share", "label": "Offering Price Per Share", "terseLabel": "Offering price per share (in USD per share)" } } }, "localname": "OfferingPricePerShare", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" ], "xbrltype": "perShareItemType" }, "adc_OperatingSegmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Segments [Abstract]", "label": "Operating Segments [Abstract]", "terseLabel": "Operating Segments [Abstract]" } } }, "localname": "OperatingSegmentsAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_OtherIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Income (Expense)", "label": "Other Income (Expense) [Abstract]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherIncomeExpenseAbstract", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "stringItemType" }, "adc_OtherNonOperatingIncome": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 1.0, "parentTag": "adc_OtherNonOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Non-Operating Income", "label": "Other Non-Operating Income", "terseLabel": "Non-operating (expense) income" } } }, "localname": "OtherNonOperatingIncome", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "adc_OtherNonOperatingIncomeExpense": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Non-Operating Income (Expense)", "label": "Other Non-Operating Income (Expense)", "totalLabel": "Total other (expense) income" } } }, "localname": "OtherNonOperatingIncomeExpense", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "adc_OutsideOfTheUnitedStatesAndEuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outside Of The United States And Europe", "label": "Outside Of The United States And Europe [Member]", "terseLabel": "Outside Of The United States And Europe" } } }, "localname": "OutsideOfTheUnitedStatesAndEuropeMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_OutstandingWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding Warrants", "label": "Outstanding Warrants [Member]", "terseLabel": "Outstanding Warrants" } } }, "localname": "OutstandingWarrantsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adc_OverlandADCTBioPharmaCYLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Overland ADCT BioPharma (CY) Limited", "label": "Overland ADCT BioPharma (CY) Limited [Member]", "terseLabel": "Overland ADCT BioPharma" } } }, "localname": "OverlandADCTBioPharmaCYLimitedMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails", "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails", "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_PaymentForRentDeposits": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment For Rent Deposits", "label": "Payment For Rent Deposits", "negatedTerseLabel": "Payment for deposits" } } }, "localname": "PaymentForRentDeposits", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_PaymentTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment Type", "label": "Payment Type [Axis]", "terseLabel": "Payment Type [Axis]" } } }, "localname": "PaymentTypeAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "adc_PaymentTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment Type [Domain]", "label": "Payment Type [Domain]", "terseLabel": "Payment Type [Domain]" } } }, "localname": "PaymentTypeDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_PaymentsMadeUnderRoyaltyFinancingTransactions": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments Made Under Royalty Financing Transactions", "label": "Payments Made Under Royalty Financing Transactions", "negatedTerseLabel": "Interest paid under royalty financing transaction" } } }, "localname": "PaymentsMadeUnderRoyaltyFinancingTransactions", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_PensionObligationDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pension Obligation, Discount Rate", "label": "Pension Obligation, Discount Rate", "terseLabel": "Pension Obligation, Discount Rate" } } }, "localname": "PensionObligationDiscountRate", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" ], "xbrltype": "percentItemType" }, "adc_PlanNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan Name", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "stringItemType" }, "adc_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan Name [Domain]", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "domainItemType" }, "adc_PlanNameMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan Name", "label": "Plan Name [Member]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "domainItemType" }, "adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Deferred Royalty Transaction, Net Of Transaction Costs", "label": "Proceeds From Deferred Royalty Transaction, Net Of Transaction Costs", "terseLabel": "Proceeds from deferred royalty transaction, net of transaction costs" } } }, "localname": "ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "adc_ProceedsFromLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds From License Agreement", "label": "Proceeds From License Agreement", "terseLabel": "Proceeds From License Agreement" } } }, "localname": "ProceedsFromLicenseAgreement", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_ProceedsFromRoyaltyPurchaseAgreementGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Royalty Purchase Agreement, Gross", "label": "Proceeds From Royalty Purchase Agreement, Gross", "terseLabel": "Proceeds From Royalty Purchase Agreement, Gross" } } }, "localname": "ProceedsFromRoyaltyPurchaseAgreementGross", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_ProceedsFromRoyaltyPurchaseAgreementNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Royalty Purchase Agreement, Net", "label": "Proceeds From Royalty Purchase Agreement, Net", "terseLabel": "Proceeds From Royalty Purchase Agreement, Net" } } }, "localname": "ProceedsFromRoyaltyPurchaseAgreementNet", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_ProductRevenueNetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Revenue, Net", "label": "Product Revenue, Net [Member]", "terseLabel": "Product revenues, net" } } }, "localname": "ProductRevenueNetMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "domainItemType" }, "adc_PurchasersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchasers", "label": "Purchasers [Member]", "terseLabel": "Purchasers" } } }, "localname": "PurchasersMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "adc_RecoveryRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recovery Rate", "label": "Recovery Rate [Member]", "terseLabel": "Recovery Rate [Member]" } } }, "localname": "RecoveryRateMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_RelatedPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party [Abstract]", "label": "Related Party [Abstract]" } } }, "localname": "RelatedPartyAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Expense", "label": "Research And Development Expense [Member]", "terseLabel": "R&D expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails" ], "xbrltype": "domainItemType" }, "adc_ResidualLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Residual Loan", "label": "Residual Loan [Member]", "terseLabel": "Residual Loan" } } }, "localname": "ResidualLoanMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" ], "xbrltype": "domainItemType" }, "adc_RestrictedShareUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Share Units (RSU)", "label": "Restricted Share Units (RSU) [Member]", "terseLabel": "Restricted Share Units (RSU)" } } }, "localname": "RestrictedShareUnitsRSUMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "domainItemType" }, "adc_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units", "label": "Restricted Stock Units [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "domainItemType" }, "adc_RevenueFromContractsWithCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From Contracts With Customers [Abstract]", "label": "Revenue From Contracts With Customers [Abstract]" } } }, "localname": "RevenueFromContractsWithCustomersAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_RiskFreeInterestRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk Free, Interest Rate", "label": "Risk Free, Interest Rate [Member]", "terseLabel": "Risk Free, Interest Rate" } } }, "localname": "RiskFreeInterestRateMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_RoyaltyObligationExpectedFutureTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty Obligation, Expected Future Transaction Costs", "label": "Royalty Obligation, Expected Future Transaction Costs", "terseLabel": "Royalty Obligation, Expected Future Transaction Costs" } } }, "localname": "RoyaltyObligationExpectedFutureTransactionCosts", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment", "label": "Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment", "terseLabel": "Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment" } } }, "localname": "RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_RoyaltyObligationInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty Obligation, Interest", "label": "Royalty Obligation, Interest", "terseLabel": "Royalty Obligation, Interest" } } }, "localname": "RoyaltyObligationInterest", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_RoyaltyObligationPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty Obligation, Payments", "label": "Royalty Obligation, Payments", "terseLabel": "Royalty Obligation, Payments" } } }, "localname": "RoyaltyObligationPayments", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_RoyaltyObligationTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty Obligation, Transaction Costs", "label": "Royalty Obligation, Transaction Costs", "terseLabel": "Royalty Obligation, Transaction Costs" } } }, "localname": "RoyaltyObligationTransactionCosts", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_RoyaltyPurchaseAdditionalProceedsEligibility": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Additional Proceeds Eligibility", "label": "Royalty Purchase Additional Proceeds Eligibility", "terseLabel": "Royalty Purchase Additional Proceeds Eligibility" } } }, "localname": "RoyaltyPurchaseAdditionalProceedsEligibility", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_RoyaltyPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement", "label": "Royalty Purchase Agreement", "terseLabel": "Royalty Purchase Agreement" } } }, "localname": "RoyaltyPurchaseAgreement", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "monetaryItemType" }, "adc_RoyaltyPurchaseAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement", "label": "Royalty Purchase Agreement [Axis]", "terseLabel": "Royalty Purchase Agreement [Axis]" } } }, "localname": "RoyaltyPurchaseAgreementAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "stringItemType" }, "adc_RoyaltyPurchaseAgreementBuyoutAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Buyout Amount", "label": "Royalty Purchase Agreement, Buyout Amount", "terseLabel": "Royalty Purchase Agreement, Buyout Amount" } } }, "localname": "RoyaltyPurchaseAgreementBuyoutAmount", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Buyout Percent, Continued Payment", "label": "Royalty Purchase Agreement, Buyout Percent, Continued Payment", "terseLabel": "Royalty Purchase Agreement, Buyout Percent, Continued Payment" } } }, "localname": "RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementBuyoutPercentPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Buyout Percent, Payment", "label": "Royalty Purchase Agreement, Buyout Percent, Payment", "terseLabel": "Royalty Purchase Agreement, Buyout Percent, Payment" } } }, "localname": "RoyaltyPurchaseAgreementBuyoutPercentPayment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement [Domain]", "label": "Royalty Purchase Agreement [Domain]", "terseLabel": "Royalty Purchase Agreement [Domain]" } } }, "localname": "RoyaltyPurchaseAgreementDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_RoyaltyPurchaseAgreementEffectiveInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Effective Interest Rate", "label": "Royalty Purchase Agreement, Effective Interest Rate", "terseLabel": "Royalty Purchase Agreement, Effective Interest Rate" } } }, "localname": "RoyaltyPurchaseAgreementEffectiveInterestRate", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, High-Single-Digit Percentage Rate", "label": "Royalty Purchase Agreement, High-Single-Digit Percentage Rate", "terseLabel": "Royalty Purchase Agreement, High-Single-Digit Percentage Rate" } } }, "localname": "RoyaltyPurchaseAgreementHighSingleDigitPercentageRate", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses", "label": "Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses", "terseLabel": "Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses" } } }, "localname": "RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Payment Percent On Net Sales", "label": "Royalty Purchase Agreement, Payment Percent On Net Sales", "terseLabel": "Royalty Purchase Agreement, Payment Percent On Net Sales" } } }, "localname": "RoyaltyPurchaseAgreementPaymentPercentOnNetSales", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit", "label": "Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit [Member]", "terseLabel": "Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit" } } }, "localname": "RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Royalties Paid Under Agreement", "label": "Royalty Purchase Agreement, Royalties Paid Under Agreement [Member]", "terseLabel": "Royalty Purchase Agreement, Royalties Paid Under Agreement" } } }, "localname": "RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_RoyaltyPurchaseAgreementRoyaltyCap": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Royalty Cap", "label": "Royalty Purchase Agreement, Royalty Cap", "terseLabel": "Royalty Purchase Agreement, Royalty Cap" } } }, "localname": "RoyaltyPurchaseAgreementRoyaltyCap", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Royalty Cap, Payment Maximum", "label": "Royalty Purchase Agreement, Royalty Cap, Payment Maximum", "terseLabel": "Royalty Purchase Agreement, Royalty Cap, Payment Maximum" } } }, "localname": "RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Royalty Cap, Period Of Payment", "label": "Royalty Purchase Agreement, Royalty Cap, Period Of Payment", "terseLabel": "Royalty Purchase Agreement, Royalty Cap, Period Of Payment" } } }, "localname": "RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "durationItemType" }, "adc_RoyaltyPurchaseAgreementRoyaltyRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Royalty Rate Percent", "label": "Royalty Purchase Agreement, Royalty Rate Percent", "terseLabel": "Royalty Purchase Agreement, Royalty Rate Percent" } } }, "localname": "RoyaltyPurchaseAgreementRoyaltyRatePercent", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_RoyaltyPurchaseAgreementTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Termination Period", "label": "Royalty Purchase Agreement, Termination Period", "terseLabel": "Royalty Purchase Agreement, Termination Period" } } }, "localname": "RoyaltyPurchaseAgreementTerminationPeriod", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "durationItemType" }, "adc_RoyaltyPurchaseAgreementTermsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement Terms", "label": "Royalty Purchase Agreement Terms [Axis]", "terseLabel": "Royalty Purchase Agreement Terms [Axis]" } } }, "localname": "RoyaltyPurchaseAgreementTermsAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "stringItemType" }, "adc_RoyaltyPurchaseAgreementTermsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement Terms [Domain]", "label": "Royalty Purchase Agreement Terms [Domain]", "terseLabel": "Royalty Purchase Agreement Terms [Domain]" } } }, "localname": "RoyaltyPurchaseAgreementTermsDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests", "label": "Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests", "negatedTerseLabel": "Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests" } } }, "localname": "RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "percentItemType" }, "adc_SaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock", "label": "Sale Of Stock [Axis]", "terseLabel": "Sale Of Stock [Axis]" } } }, "localname": "SaleOfStockAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "adc_SaleOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock", "label": "Sale Of Stock [Domain]", "terseLabel": "Sale Of Stock [Domain]" } } }, "localname": "SaleOfStockDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "adc_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Price Per Share", "label": "Sale Of Stock, Price Per Share", "terseLabel": "Sale Of Stock, Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "adc_SecondInvestmentAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Investment Amount", "label": "Second Investment Amount [Member]", "terseLabel": "Second Investment Amount" } } }, "localname": "SecondInvestmentAmountMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_SecuredOvernightFinancingRateSOFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR)" } } }, "localname": "SecuredOvernightFinancingRateSOFRMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_SeniorSecuredTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Term Loan Facility", "label": "Senior Secured Term Loan Facility [Member]", "terseLabel": "Senior Secured Term Loan Facility" } } }, "localname": "SeniorSecuredTermLoanFacilityMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/FinancialriskmanagementDetails", "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_SeniorSecuredTermLoanFacilityTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Term Loan Facility, Tranche One", "label": "Senior Secured Term Loan Facility, Tranche One [Member]", "terseLabel": "Senior Secured Term Loan Facility, Tranche One" } } }, "localname": "SeniorSecuredTermLoanFacilityTrancheOneMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_SeniorSecuredTermLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Term Loans", "label": "Senior Secured Term Loans [Member]", "terseLabel": "Senior Secured Term Loans" } } }, "localname": "SeniorSecuredTermLoansMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Increase (Decrease) In Derivative", "label": "Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Increase (Decrease) In Derivative", "terseLabel": "Value of change in derivative" } } }, "localname": "SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Percent", "label": "Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Percent", "terseLabel": "Increase (decrease) in estimated probability of derivative" } } }, "localname": "SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "percentItemType" }, "adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Decrease On Derivative Values", "label": "Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Decrease On Derivative Values", "terseLabel": "Sensitivity analysis for types of interest rate risk, reasonably possible change in risk variable, decrease on derivative values" } } }, "localname": "SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/FinancialriskmanagementDetails" ], "xbrltype": "monetaryItemType" }, "adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Increase On Derivative Values", "label": "Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Increase On Derivative Values", "terseLabel": "Sensitivity analysis for types of interest rate risk, reasonably possible change in risk variable, increase on derivative values" } } }, "localname": "SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/FinancialriskmanagementDetails" ], "xbrltype": "monetaryItemType" }, "adc_ServicesProvidedRelatedPartyTransactions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Services Provided, Related Party Transactions", "label": "Services Provided, Related Party Transactions", "terseLabel": "Services provided to, related party transactions" } } }, "localname": "ServicesProvidedRelatedPartyTransactions", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Shares Issued, Tax Withheld", "label": "Share-Based Payment Arrangement, Shares Issued, Tax Withheld", "terseLabel": "Share-Based Payment Arrangement, Shares Issued, Tax Withheld" } } }, "localname": "ShareBasedPaymentArrangementSharesIssuedTaxWithheld", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_ShareBasedPaymentArrangementSharesTransferredToParticipants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Shares Transferred To Participants", "label": "Share-Based Payment Arrangement, Shares Transferred To Participants", "terseLabel": "Share-Based Payment Arrangement, Shares Transferred To Participants" } } }, "localname": "ShareBasedPaymentArrangementSharesTransferredToParticipants", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "adc_ShareBasedPaymentArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Payment Arrangements [Abstract]", "label": "Share-based Payment Arrangements [Abstract]", "terseLabel": "Share-based Payment Arrangements [Abstract]" } } }, "localname": "ShareBasedPaymentArrangementsAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_ShareCapitalReservesAndOtherEquityInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Capital, Reserves And Other Equity Interest [Abstract]", "label": "Share Capital, Reserves And Other Equity Interest [Abstract]" } } }, "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "stringItemType" }, "adc_ShareIssueRelatedCostThroughFollowOnOffering": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 7.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": -1.0 } }, "crdr": "debit", "localname": "ShareIssueRelatedCostThroughFollowOnOffering", "nsuri": "http://adctherapeutics.com/20220930", "xbrltype": "monetaryItemType" }, "adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share Issue Related Cost Through Initial Public Offering And Over-Allotment Option", "label": "Share Issue Related Cost Through Initial Public Offering And Over-Allotment Option", "terseLabel": "Exercise of options and vestings of RSUs" } } }, "localname": "ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share Of Profit (Loss) Of Joint Ventures Accounted For Using Equity Method, Proportionate Share Of Results", "label": "Share Of Profit (Loss) Of Joint Ventures Accounted For Using Equity Method, Proportionate Share Of Results", "terseLabel": "Share of results in joint venture" } } }, "localname": "ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails" ], "xbrltype": "monetaryItemType" }, "adc_SharePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Price", "label": "Share Price [Member]", "terseLabel": "Share Price (in USD per share)" } } }, "localname": "SharePriceMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "adc_SharePurchasePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Purchase Plan 2016", "label": "Share Purchase Plan 2016 [Member]", "terseLabel": "Share Purchase Plan 2016 [Member]" } } }, "localname": "SharePurchasePlan2016Member", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "domainItemType" }, "adc_ShareSubscriptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Subscription Agreement", "label": "Share Subscription Agreement [Member]", "terseLabel": "Share Subscription Agreement" } } }, "localname": "ShareSubscriptionAgreementMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "adc_ShortTermBorrowings": { "auth_ref": [], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Short-Term Borrowings", "label": "Short-Term Borrowings", "terseLabel": "Senior secured term loans, short-term" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "adc_SpecialRetentionAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Special Retention Award", "label": "Special Retention Award [Member]", "terseLabel": "Special Retention Award" } } }, "localname": "SpecialRetentionAwardMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Successful Completion Of In-Vivo Efficacy Studies", "label": "Successful Completion Of In-Vivo Efficacy Studies [Member]", "terseLabel": "Successful Completion Of In-Vivo Efficacy Studies" } } }, "localname": "SuccessfulCompletionOfInVivoEfficacyStudiesMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Cash Flow Information", "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Non-Cash Investing Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "stringItemType" }, "adc_SuppliesProvidedRelatedPartyTransactions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Supplies Provided, Related Party Transactions", "label": "Supplies Provided, Related Party Transactions", "terseLabel": "Supplies Provided, Related Party Transactions" } } }, "localname": "SuppliesProvidedRelatedPartyTransactions", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_TaxEffectOfResearchAndDevelopmentTaxCredits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax Effect Of Research And Development Tax Credits", "label": "Tax Effect Of Research And Development Tax Credits", "terseLabel": "Tax Effect Of Research And Development Tax Credits" } } }, "localname": "TaxEffectOfResearchAndDevelopmentTaxCredits", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "adc_ThirdInvestmentAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Investment Amount", "label": "Third Investment Amount [Member]", "terseLabel": "Third Investment Amount" } } }, "localname": "ThirdInvestmentAmountMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_TradeAndOtherCurrentReceivablesSalesAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Trade and other current receivables, Sales Adjustment", "label": "Trade and other current receivables, Sales Adjustment", "terseLabel": "Accounts receivable, net" } } }, "localname": "TradeAndOtherCurrentReceivablesSalesAdjustment", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetDetails" ], "xbrltype": "monetaryItemType" }, "adc_TrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche Four", "label": "Tranche Four [Member]", "terseLabel": "Tranche Four" } } }, "localname": "TrancheFourMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_TrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche One", "label": "Tranche One [Member]", "terseLabel": "Tranche One" } } }, "localname": "TrancheOneMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_TrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche Three", "label": "Tranche Three [Member]", "terseLabel": "Tranche Three" } } }, "localname": "TrancheThreeMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_TrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche Two", "label": "Tranche Two [Member]", "terseLabel": "Tranche Two" } } }, "localname": "TrancheTwoMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_TransfersIntangibleAssetsOtherThanGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transfers, Intangible Assets Other Than Goodwill", "label": "Transfers, Intangible Assets Other Than Goodwill", "terseLabel": "Transfers" } } }, "localname": "TransfersIntangibleAssetsOtherThanGoodwill", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "adc_VestingPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Period", "label": "Vesting Period [Axis]", "terseLabel": "Vesting Period [Axis]" } } }, "localname": "VestingPeriodAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "adc_VestingPeriodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Period", "label": "Vesting Period [Member]", "terseLabel": "Vesting Period" } } }, "localname": "VestingPeriodMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentage", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "adc_WarrantObligationFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Obligation, Fair Value", "label": "Warrant Obligation, Fair Value", "terseLabel": "Warrant Obligation, Fair Value" } } }, "localname": "WarrantObligationFairValue", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "adc_WarrantObligationsTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrant Obligations, Transaction Costs", "label": "Warrant Obligations, Transaction Costs", "terseLabel": "Warrant Obligations, Transaction Costs" } } }, "localname": "WarrantObligationsTransactionCosts", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "adc_WarrantsSharesConvertedExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, Shares Converted, Exercise Price", "label": "Warrants, Shares Converted, Exercise Price", "terseLabel": "Warrants, Shares Converted, Exercise Price" } } }, "localname": "WarrantsSharesConvertedExercisePrice", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "adc_WarrantsTrancheAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, Tranche", "label": "Warrants, Tranche [Axis]", "terseLabel": "Warrants, Tranche [Axis]" } } }, "localname": "WarrantsTrancheAxis", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/EquityDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "adc_WarrantsTrancheDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, Tranche [Domain]", "label": "Warrants, Tranche [Domain]", "terseLabel": "Warrants, Tranche [Domain]" } } }, "localname": "WarrantsTrancheDomain", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/EquityDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "adc_WarrantsTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, Tranche One", "label": "Warrants, Tranche One [Member]", "terseLabel": "Warrants, Tranche One" } } }, "localname": "WarrantsTrancheOneMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "adc_WarrantsTrancheOnePriceOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, Tranche One, Price One", "label": "Warrants, Tranche One, Price One [Member]", "terseLabel": "Warrants, Tranche One, Price One" } } }, "localname": "WarrantsTrancheOnePriceOneMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "adc_WarrantsTrancheOnePriceTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, Tranche One, Price Two", "label": "Warrants, Tranche One, Price Two [Member]", "terseLabel": "Warrants, Tranche One, Price Two" } } }, "localname": "WarrantsTrancheOnePriceTwoMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "adc_WarrantsTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, Tranche Two", "label": "Warrants, Tranche Two [Member]", "terseLabel": "Warrants, Tranche Two" } } }, "localname": "WarrantsTrancheTwoMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price Of Share Options Vested And Exercisable In Share-Based Payment Arrangement", "label": "Weighted Average Exercise Price Of Share Options Vested And Exercisable In Share-Based Payment Arrangement", "terseLabel": "Weighted average strike price, vested and exercisable (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Fair Value At Measurement Date Per Share, Share Options Granted", "label": "Weighted Average Fair Value At Measurement Date Per Share, Share Options Granted", "terseLabel": "Weighted-average grant-date fair value (in dollars per share)" } } }, "localname": "WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Forfeited", "label": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Forfeited", "terseLabel": "Weighted average grant date fair value, forfeited (in dollars per share)" } } }, "localname": "WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Granted", "label": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Granted", "terseLabel": "Weighted average grant date fair value, granted (in USD per share)" } } }, "localname": "WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Outstanding", "label": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Outstanding", "periodEndLabel": "Weighted average grant date fair value, ending balance (in USD per share)", "periodStartLabel": "Weighted average grant date fair value, beginning balance (in USD per share)" } } }, "localname": "WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Vested", "label": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Vested", "terseLabel": "Weighted average grant date fair value, vested (in dollars per share)" } } }, "localname": "WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Contractual Life Of Granted Share Options", "label": "Weighted Average Remaining Contractual Life Of Granted Share Options", "terseLabel": "Weighted average remaining contractual life of granted share options" } } }, "localname": "WeightedAverageRemainingContractualLifeOfGrantedShareOptions", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "durationItemType" }, "adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Contractual Life Of Outstanding Share Options", "label": "Weighted Average Remaining Contractual Life Of Outstanding Share Options", "terseLabel": "Weighted average remaining life, vested and exercisable" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea)", "label": "Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea) [Member]", "terseLabel": "Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea)" } } }, "localname": "WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_WorldwideMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Worldwide", "label": "Worldwide [Member]", "terseLabel": "Worldwide" } } }, "localname": "WorldwideMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "adc_ZYNLONTAForRDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ZYNLONTA For R&D", "label": "ZYNLONTA For R&D [Member]", "terseLabel": "ZYNLONTA For R&D" } } }, "localname": "ZYNLONTAForRDMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "adc_ZYNLONTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ZYNLONTA", "label": "ZYNLONTA [Member]", "terseLabel": "ZYNLONTA" } } }, "localname": "ZYNLONTAMember", "nsuri": "http://adctherapeutics.com/20220930", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails", "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adctherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "auth_ref": [ "r56", "r59", "r92", "r103", "r106" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation and amortisation [member]", "terseLabel": "Accumulated amortization" } } }, "localname": "AccumulatedDepreciationAndAmortisationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails", "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails", "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r164" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "Additions" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForAmortisationExpense": { "auth_ref": [ "r118" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Adjustments for amortisation expense", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AdjustmentsForAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": { "auth_ref": [ "r118" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other assets", "terseLabel": "Decrease (increase) in other current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": { "auth_ref": [ "r118" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other current assets", "terseLabel": "Decrease (increase) in other current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "auth_ref": [ "r115" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade accounts receivable", "terseLabel": "Decrease (increase) in accounts receivable, net" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceCosts": { "auth_ref": [ "r117" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance costs", "terseLabel": "Financial expense" } } }, "localname": "AdjustmentsForFinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncome": { "auth_ref": [ "r118" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance income", "negatedTerseLabel": "Financial income" } } }, "localname": "AdjustmentsForFinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": { "auth_ref": [ "r118" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for gains (losses) on change in fair value of derivatives", "negatedTerseLabel": "Convertible loans, derivatives, decrease in fair value" } } }, "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories": { "auth_ref": [ "r118" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 16.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) on inventories recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]" } }, "en-us": { "role": { "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, inventories", "terseLabel": "Gain from reversal of inventory impairment charges" } } }, "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "http://adctherapeutics.com/role/InventoriesNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "auth_ref": [ "r122" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Increase in income taxes" } } }, "localname": "AdjustmentsForIncomeTaxExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in other liabilities", "terseLabel": "Increase in other liabilities and other payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r118" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "(Decrease) increase in accounts payable" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments for non-monetary items:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r116" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r116", "r125" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange differences" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r94" ], "lang": { "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "negatedTerseLabel": "Amortisation, intangible assets other than goodwill", "terseLabel": "Amortisation, intangible assets other than goodwill" } } }, "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails", "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "auth_ref": [ "r72", "r75" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts receivable, related party transactions", "terseLabel": "Amounts receivable, related party transactions" } } }, "localname": "AmountsReceivableRelatedPartyTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Analysis of income and expense [abstract]" } } }, "localname": "AnalysisOfIncomeAndExpenseAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r22", "r147", "r148", "r150", "r203", "r205" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_AverageForeignExchangeRate": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } }, "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average foreign exchange rate" } } }, "localname": "AverageForeignExchangeRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r82", "r83" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Net loss per share, basic (in USD per share)" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/LosspershareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_Borrowings": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } }, "en-us": { "role": { "label": "Borrowings", "terseLabel": "Borrowings" } } }, "localname": "Borrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BorrowingsByNameAxis": { "auth_ref": [ "r198" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Borrowings by name [axis]", "terseLabel": "Borrowings by name [axis]" } } }, "localname": "BorrowingsByNameAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails", "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/FinancialriskmanagementDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameMember": { "auth_ref": [ "r198" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings by name [member]", "terseLabel": "Borrowings by name" } } }, "localname": "BorrowingsByNameMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails", "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/FinancialriskmanagementDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r198" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Borrowings, interest rate" } } }, "localname": "BorrowingsInterestRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BuildingsMember": { "auth_ref": [ "r55" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Buildings [member]", "terseLabel": "Properties (Offices)" } } }, "localname": "BuildingsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails", "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r56", "r58", "r92", "r96", "r102", "r103", "r104", "r105", "r106", "r184", "r191", "r192", "r220", "r222" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails", "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r58", "r96", "r102", "r104", "r105", "r184", "r191", "r192", "r220", "r221" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying amount [member]", "terseLabel": "Carrying amount" } } }, "localname": "CarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails", "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r19", "r123", "r142" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 }, "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": { "order": 1.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at end of the period", "periodStartLabel": "Cash and cash equivalents at beginning of the period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r107", "r124" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash (used in) provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r107", "r124" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash used in investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r107", "r124" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperations": { "auth_ref": [ "r118", "r125" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } }, "en-us": { "role": { "label": "Cash flows from (used in) operations", "totalLabel": "Cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "auth_ref": [ "r118", "r125" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } }, "en-us": { "role": { "label": "Cash flows from (used in) operations before changes in working capital", "totalLabel": "Operating loss before working capital changes" } } }, "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashOutflowForLeases": { "auth_ref": [ "r163" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for leases." } }, "en-us": { "role": { "label": "Cash outflow for leases", "negatedTerseLabel": "Cash outflow (including interest)" } } }, "localname": "CashOutflowForLeases", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r74" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]", "terseLabel": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r87", "r90", "r152", "r166" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]", "terseLabel": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r87", "r152", "r166" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]", "terseLabel": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]", "terseLabel": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails", "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfLiabilitiesAxis": { "auth_ref": [ "r152" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of liabilities [axis]", "terseLabel": "Classes of liabilities [axis]" } } }, "localname": "ClassesOfLiabilitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClosingForeignExchangeRate": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } }, "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Closing foreign exchange rate" } } }, "localname": "ClosingForeignExchangeRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]", "terseLabel": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, before tax [abstract]", "terseLabel": "Other comprehensive (loss) income" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]", "terseLabel": "Items that may be reclassified to profit and loss" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r4", "r37", "r128", "r130", "r135", "r140" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "terseLabel": "Total comprehensive loss for the period", "totalLabel": "Total comprehensive loss for the period" } } }, "localname": "ComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive income attributable to [abstract]", "terseLabel": "Total comprehensive loss attributable to:" } } }, "localname": "ComprehensiveIncomeAttributableToAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "auth_ref": [ "r4", "r39" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive income, attributable to owners of parent", "totalLabel": "Owners of the parent" } } }, "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComputerSoftwareMember": { "auth_ref": [ "r98" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Computer software [member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures": { "auth_ref": [ "r134" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of contingent liabilities incurred in relation to interests in joint ventures. [Refer: Contingent liabilities [member]; Joint ventures [member]]" } }, "en-us": { "role": { "label": "Contingent liabilities incurred in relation to interests in joint ventures", "terseLabel": "Deferred gain of joint venture" } } }, "localname": "ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CostOfSales": { "auth_ref": [ "r2", "r46" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 4.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } }, "en-us": { "role": { "label": "Cost of sales", "negatedTerseLabel": "Cost of product sales", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfSales", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CreditDerivativeFairValue": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The fair value of a credit derivative. [Refer: At fair value [member]; Derivatives [member]]" } }, "en-us": { "role": { "label": "Credit derivative, fair value", "terseLabel": "Credit derivative, fair value" } } }, "localname": "CreditDerivativeFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } }, "en-us": { "role": { "label": "Current accrued expenses and other current liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r23", "r135", "r136" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Current borrowings and current portion of non-current borrowings", "terseLabel": "Convertible loans, short-term" } } }, "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r160" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Lease liabilities, short-term" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r25", "r135", "r138" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": { "order": 4.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } }, "en-us": { "role": { "label": "Current prepayments and other current assets", "terseLabel": "Prepaid and other current assets" } } }, "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } }, "en-us": { "role": { "label": "Current tax liabilities, current", "terseLabel": "Current income tax payable" } } }, "localname": "CurrentTaxLiabilitiesCurrent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedLabel": "Depreciation charge", "terseLabel": "Depreciation, right-of-use assets" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails", "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DerivativesMember": { "auth_ref": [ "r153", "r155", "r197", "r200" ], "lang": { "en": { "role": { "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Derivatives [member]", "terseLabel": "Derivatives", "verboseLabel": "Derivatives" } } }, "localname": "DerivativesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r207", "r217" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation." } }, "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Functional and reporting currency" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r207", "r217" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax." } }, "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Income tax expense" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "auth_ref": [ "r207", "r217" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue Recognition" } } }, "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Disclosure of initial application of standards or interpretations [text block]", "terseLabel": "New and amended IFRS standards" } } }, "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Award life" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r82", "r83" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Net loss per share, diluted (in dollars per share)" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/LosspershareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "Disclosure of attribution of expenses by nature to their function [line items]" } } }, "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "auth_ref": [ "r3", "r11" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss." } }, "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]", "terseLabel": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of preparation" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Basisofpreparation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Cashandcashequivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Disclosure of classes of share capital [line items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]", "terseLabel": "Disclosure of classes of share capital [table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDebtSecuritiesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]" } }, "en-us": { "role": { "label": "Disclosure of debt instruments [text block]", "terseLabel": "Convertible loans" } } }, "localname": "DisclosureOfDebtSecuritiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Convertibleloans", "http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "auth_ref": [ "r198" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of borrowings" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansTables", "http://adctherapeutics.com/role/Deferredroyaltyobligation", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Disclosure of detailed information about borrowings [line items]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails", "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r198" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]", "terseLabel": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails", "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails", "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r188", "r193", "r198" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of Derivative Option and Convertible Loan" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r159" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]", "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r85" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Loss per share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Losspershare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r49" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Events after the reporting date" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Eventsafterthereportingdate" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Disclosure of expenses by nature [text block]", "terseLabel": "Operating expense" } } }, "localname": "DisclosureOfExpensesByNatureExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Operatingexpense" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Disclosure of detailed information about financial instruments [line items]" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/FinancialriskmanagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r188", "r193", "r198" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]", "terseLabel": "Disclosure of detailed information about financial instruments [table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/FinancialriskmanagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } }, "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Financial risk management" } } }, "localname": "DisclosureOfFinancialRiskManagementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Financialriskmanagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "auth_ref": [ "r14" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } }, "en-us": { "role": { "label": "Disclosure of general information about financial statements [text block]", "terseLabel": "Corporate information" } } }, "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Corporateinformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r181" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "terseLabel": "Schedule of Fair Value Assumption For Options Granted" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "auth_ref": [ "r101" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for intangible assets." } }, "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible assets" } } }, "localname": "DisclosureOfIntangibleAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Intangibleassets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "terseLabel": "Disclosure of detailed information about intangible assets [line items]" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails", "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]", "terseLabel": "Disclosure of detailed information about intangible assets [table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory": { "auth_ref": [ "r133" ], "lang": { "en": { "role": { "documentation": "The disclosure of interests in joint arrangements. A joint arrangement is an arrangement of which two or more parties have joint control." } }, "en-us": { "role": { "label": "Disclosure of interests in joint arrangements [text block]", "terseLabel": "Schedule of movement in interest in joint venture" } } }, "localname": "DisclosureOfInterestsInJointArrangementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Schedule of consolidated entities" } } }, "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for inventories." } }, "en-us": { "role": { "label": "Disclosure of inventories [text block]", "terseLabel": "Disclosure of inventories [text block]" } } }, "localname": "DisclosureOfInventoriesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfJointVenturesExplanatory": { "auth_ref": [ "r78", "r79", "r146" ], "lang": { "en": { "role": { "documentation": "The disclosure of joint ventures. [Refer: Joint ventures [member]]" } }, "en-us": { "role": { "label": "Disclosure of joint ventures [text block]", "terseLabel": "Interest in joint venture" } } }, "localname": "DisclosureOfJointVenturesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Interestinjointventure" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfJointVenturesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of joint ventures [line items]", "terseLabel": "Disclosure of joint ventures [line items]" } } }, "localname": "DisclosureOfJointVenturesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails", "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfJointVenturesTable": { "auth_ref": [ "r78", "r79", "r146" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to joint ventures." } }, "en-us": { "role": { "label": "Disclosure of joint ventures [table]", "terseLabel": "Disclosure of joint ventures [table]" } } }, "localname": "DisclosureOfJointVenturesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails", "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r167", "r168" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Leases" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]", "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "auth_ref": [ "r48" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]", "terseLabel": "Disclosure of non-adjusting events after reporting period [table]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of Other Equity Instruments Outstanding" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of Shares Outstanding" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": { "auth_ref": [ "r178" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options." } }, "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]", "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "auth_ref": [ "r203" ], "lang": { "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } }, "en-us": { "role": { "label": "Disclosure of operating segments [text block]", "terseLabel": "Segment information" } } }, "localname": "DisclosureOfOperatingSegmentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Segmentinformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "auth_ref": [ "r166" ], "lang": { "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of quantitative information about right-of-use assets" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]", "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails", "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "auth_ref": [ "r166" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]", "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails", "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } }, "en-us": { "role": { "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]", "terseLabel": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]" } } }, "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory": { "auth_ref": [ "r144" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of the summarised financial information of a joint venture accounted for using the equity method to the carrying amount of the reporting entity's interest in the joint venture. [Refer: Carrying amount [member]; Joint ventures [member]]" } }, "en-us": { "role": { "label": "Disclosure of reconciliation of summarised financial information of joint venture accounted for using equity method to carrying amount of interest in joint venture [text block]", "terseLabel": "Summary of financial information in join venture" } } }, "localname": "DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r76" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related parties" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Relatedparties" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReservesWithinEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of reserves within equity [line items]", "terseLabel": "Disclosure of reserves within equity [line items]" } } }, "localname": "DisclosureOfReservesWithinEquityLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReservesWithinEquityTable": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to reserves within equity." } }, "en-us": { "role": { "label": "Disclosure of reserves within equity [table]", "terseLabel": "Disclosure of reserves within equity [table]" } } }, "localname": "DisclosureOfReservesWithinEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRevenueExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for revenue." } }, "en-us": { "role": { "label": "Disclosure of revenue [text block]", "verboseLabel": "Product revenue, net" } } }, "localname": "DisclosureOfRevenueExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Productrevenuesnet" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Equity" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Share-based compensation" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Sharebasedcompensation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]", "terseLabel": "Disclosure of subsidiaries [line items]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "auth_ref": [ "r78", "r79", "r145" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } }, "en-us": { "role": { "label": "Disclosure of subsidiaries [table]", "terseLabel": "Disclosure of subsidiaries [table]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory": { "auth_ref": [ "r149" ], "lang": { "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of the entity's own equity instruments. [Refer: Entity's own equity instruments [member]]" } }, "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of equity [text block]", "terseLabel": "Schedule of valuation inputs" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/DeerfieldWarrantsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": { "auth_ref": [ "r149" ], "lang": { "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities." } }, "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]", "terseLabel": "Schedule of key inputs used for valuation" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansTables", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r218" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Significant accounting policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/Significantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails", "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]", "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Key Management Compensation" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "terseLabel": "Disclosure of transactions between related parties [line items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r74" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]", "terseLabel": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share [abstract]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r82" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of loss per share and potentially dilutive securities" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LosspershareTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Earnings per share [line items]", "terseLabel": "Earnings per share [line items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareTable": { "auth_ref": [ "r82" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [table]", "terseLabel": "Earnings per share [table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r119", "r120" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange losses on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForJointVenturesMember": { "auth_ref": [ "r78", "r79", "r146", "r216", "r219" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Joint ventures' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for joint ventures [member]", "terseLabel": "Entity's total for joint ventures [member]" } } }, "localname": "EntitysTotalForJointVenturesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails", "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r74" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]", "terseLabel": "Entity's total for related parties" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r22", "r29", "r127", "r129", "r147", "r148", "r150" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "totalLabel": "Total equity attributable to owners of the parent" } } }, "localname": "Equity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Equity attributable to owners of the parent" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]", "terseLabel": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "The exercise price of share options granted." } }, "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Strike price (in USD per share)" } } }, "localname": "ExercisePriceShareOptionsGranted2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExpectedDividendShareOptionsGranted": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "The amount of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected dividend, share options granted", "terseLabel": "Expected dividends" } } }, "localname": "ExpectedDividendShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "terseLabel": "Expense recognized" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r40" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 3.0, "parentTag": "adc_OtherNonOperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Financial expense" } } }, "localname": "FinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r43" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 2.0, "parentTag": "adc_OtherNonOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income" } } }, "localname": "FinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinishedGoods": { "auth_ref": [ "r28", "r63" ], "calculation": { "http://adctherapeutics.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "ifrs-full_InventoriesTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current finished goods", "terseLabel": "Current finished goods" } } }, "localname": "FinishedGoods", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r61" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "negatedTerseLabel": "Remeasurement of defined benefit pension liability" } } }, "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } }, "en-us": { "role": { "label": "Gains (losses) on change in fair value of derivatives", "negatedTerseLabel": "Gains (losses) on change in fair value of derivatives", "terseLabel": "Gains (losses) on change in fair value of derivatives" } } }, "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r13", "r65" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Foreign exchange gain (loss)", "terseLabel": "Foreign exchange gain (loss)" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } }, "en-us": { "role": { "label": "Gains on change in fair value of derivatives", "terseLabel": "Gains on change in fair value of derivatives" } } }, "localname": "GainsOnChangeInFairValueOfDerivatives", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r11" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 1.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedTerseLabel": "General and administrative expenses", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r56", "r92", "r103", "r106", "r184", "r192", "r194", "r195", "r220", "r222" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross carrying amount [member]", "terseLabel": "Cost" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails", "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "auth_ref": [ "r45", "r57" ], "lang": { "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Impairment loss recognised in profit or loss, property, plant and equipment", "terseLabel": "Impairment loss recognised in profit or loss, property, plant and equipment" } } }, "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "auth_ref": [ "r46" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]" } }, "en-us": { "role": { "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss", "terseLabel": "Impairments of Assets" } } }, "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r41", "r50", "r51", "r52", "r77", "r143", "r202" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedTerseLabel": "Income tax benefit (expense)" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "auth_ref": [ "r108", "r122" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } }, "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedTerseLabel": "Taxes paid" } } }, "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r123" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the fair value of a credit derivative. [Refer: Credit derivative, fair value]" } }, "en-us": { "role": { "label": "Increase (decrease) in credit derivative, fair value", "terseLabel": "Increase (decrease) in credit derivative, fair value" } } }, "localname": "IncreaseDecreaseInCreditDerivativeFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": { "auth_ref": [ "r54" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]" } }, "en-us": { "role": { "label": "Increase (decrease) in deferred tax liability (asset)", "negatedTerseLabel": "Deferred tax asset" } } }, "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "auth_ref": [ "r8" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 10.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } }, "en-us": { "role": { "label": "Increase (decrease) through exercise of options, equity", "terseLabel": "Exercise of options" } } }, "localname": "IncreaseDecreaseThroughExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill", "terseLabel": "Increase (decrease) through net exchange differences, intangible assets other than goodwill" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r7" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 9.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based compensation expense" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": { "auth_ref": [ "r8" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from transactions with owners." } }, "en-us": { "role": { "label": "Increase (decrease) through transactions with owners, equity", "totalLabel": "Total transactions with owners" } } }, "localname": "IncreaseDecreaseThroughTransactionsWithOwners", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "auth_ref": [ "r8" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 11.0, "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } }, "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Issuance of shares to be held as treasury shares" } } }, "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r16", "r96" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 }, "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": { "order": 2.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r88", "r97", "r166" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill [member]", "terseLabel": "Intangible assets other than goodwill" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails", "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpenseOnBorrowings": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } }, "en-us": { "role": { "label": "Interest expense on borrowings", "terseLabel": "Interest expense on borrowings" } } }, "localname": "InterestExpenseOnBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r162" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "terseLabel": "Interest expense on lease obligations", "verboseLabel": "Interest" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } }, "en-us": { "role": { "label": "Interest paid, classified as operating activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestRateRiskMember": { "auth_ref": [ "r201", "r210", "r211", "r212", "r213" ], "lang": { "en": { "role": { "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Interest rate risk [member]", "terseLabel": "Interest rate risk" } } }, "localname": "InterestRateRiskMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/FinancialriskmanagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestRateTypesMember": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Interest rate types [member]", "terseLabel": "Interest rate types [member]" } } }, "localname": "InterestRateTypesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } }, "en-us": { "role": { "label": "Interest received, classified as operating activities", "terseLabel": "Interest received" } } }, "localname": "InterestReceivedClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r17", "r24", "r62" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventory" } } }, "localname": "Inventories", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InventoriesTotal": { "auth_ref": [ "r17" ], "calculation": { "http://adctherapeutics.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]" } }, "en-us": { "role": { "label": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoriesTotal", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Investments in joint ventures accounted for using equity method", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Interest in joint venture" } } }, "localname": "InvestmentsInJointVenturesAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r29" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Share Capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_JointVenturesAxis": { "auth_ref": [ "r78", "r79", "r146", "r216", "r219" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Joint ventures [axis]", "terseLabel": "Joint ventures [axis]" } } }, "localname": "JointVenturesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails", "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Key management compensation" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": { "auth_ref": [ "r69" ], "calculation": { "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": { "order": 4.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, other long-term employee benefits", "terseLabel": "Other compensation" } } }, "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r68" ], "calculation": { "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": { "order": 1.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, post-employment benefits", "terseLabel": "Pension costs" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r70" ], "calculation": { "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": { "order": 2.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based compensation expense" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r67" ], "calculation": { "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": { "order": 3.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Salaries and other short-term employee costs" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r160" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "LeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r22", "r147", "r148", "r150", "r203", "r206" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 }, "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": { "order": 3.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesMember": { "auth_ref": [ "r152" ], "lang": { "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } }, "en-us": { "role": { "label": "Liabilities [member]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LicencesMember": { "auth_ref": [ "r99" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Licences [member]", "terseLabel": "Licences [member]" } } }, "localname": "LicencesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LoansReceived": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of loans received." } }, "en-us": { "role": { "label": "Loans received", "terseLabel": "Loans received" } } }, "localname": "LoansReceived", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LongtermBorrowings": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Convertible loans, long-term" } } }, "localname": "LongtermBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetAssetsLiabilities": { "auth_ref": [ "r11", "r131" ], "calculation": { "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } }, "en-us": { "role": { "label": "Assets (liabilities)", "totalLabel": "Net assets" } } }, "localname": "NetAssetsLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetDeferredTaxAssets": { "auth_ref": [ "r53" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Net deferred tax assets", "terseLabel": "Deferred tax asset" } } }, "localname": "NetDeferredTaxAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r48" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]", "terseLabel": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r48" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]", "terseLabel": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/EventsafterthereportingdateDetails", "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r23", "r135", "r137" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } }, "en-us": { "role": { "label": "Non-current derivative financial liabilities", "terseLabel": "Convertible loans, derivatives" } } }, "localname": "NoncurrentDerivativeFinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r160" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease liabilities, long-term" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r25", "r135", "r139" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]" } }, "en-us": { "role": { "label": "Non-current net defined benefit liability", "terseLabel": "Defined benefit pension liabilities" } } }, "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentWarrantLiability": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current warrant liabilities. [Refer: Warrant liability]" } }, "en-us": { "role": { "label": "Non-current warrant liability", "terseLabel": "Warrant obligations" } } }, "localname": "NoncurrentWarrantLiability", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r170", "r183" ], "lang": { "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of instruments granted in share-based payment arrangement", "terseLabel": "Number of instruments granted in share-based payment arrangement" } } }, "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r179", "r182" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Number of awards, granted (in shares)" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "negatedLabel": "Number of awards, vested (in shares)", "terseLabel": "Shares vested (in shares)" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedTerseLabel": "Number of awards, forfeited (in shares)" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Number of awards, end of period (in shares)", "periodStartLabel": "Number of awards, beginning of period (in shares)" } } }, "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r171", "r176", "r178" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "Number of awards, At end of the year (in shares)", "periodStartLabel": "Number of awards, At beginning of the year (in shares)", "terseLabel": "Number of share options outstanding in share-based payment arrangement (in shares)" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "negatedTerseLabel": "Number of awards, Exercised (in shares)" } } }, "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options expired in share-based payment arrangement", "negatedTerseLabel": "Number of awards, Expired (in shares)" } } }, "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "negatedTerseLabel": "Number of awards, Forfeited (in shares)" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Number of awards, Granted (in shares)" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Number of shares authorised (in shares)" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Number of shares issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r43" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "negatedTotalLabel": "Total operating expense", "terseLabel": "Operating expense" } } }, "localname": "OperatingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r6", "r36", "r44", "r141" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "totalLabel": "Other comprehensive (loss) income for the period" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r26", "r44" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": { "order": 2.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 }, "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Currency translation differences", "verboseLabel": "Translation adjustment" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "auth_ref": [ "r26", "r44", "r60" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Remeasurement of defined benefit pension liability" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "auth_ref": [ "r42", "r47" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "totalLabel": "Total items that may be reclassified to profit and loss" } } }, "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "auth_ref": [ "r42", "r47" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "terseLabel": "Total items that will not be reclassified to profit and loss" } } }, "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentAssets": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentAssets": { "auth_ref": [ "r22" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } }, "en-us": { "role": { "label": "Other non-current assets", "terseLabel": "Other long-term assets" } } }, "localname": "OtherNoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r29" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves", "terseLabel": "Other reserves" } } }, "localname": "OtherReserves", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReservesMember": { "auth_ref": [ "r9", "r33" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves [member]", "terseLabel": "Other Reserves" } } }, "localname": "OtherReservesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r112" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedTerseLabel": "Principal portion of lease obligation payments" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Proceeds from convertible loans, net of transaction costs" } } }, "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromCurrentBorrowings": { "auth_ref": [ "r113" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]" } }, "en-us": { "role": { "label": "Proceeds from current borrowings", "terseLabel": "Proceeds from senior secured term loans, net of transaction costs" } } }, "localname": "ProceedsFromCurrentBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfOptions": { "auth_ref": [ "r113" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of options." } }, "en-us": { "role": { "label": "Proceeds from exercise of options", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r110" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Proceeds from equity issuance, net of transaction costs" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "http://adctherapeutics.com/role/CorporateinformationDetails", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r5", "r35", "r114", "r128", "r130", "r135", "r203", "r204", "r208", "r215" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 }, "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Loss for the period" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss", "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails", "http://adctherapeutics.com/role/LosspershareDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to [abstract]", "terseLabel": "Net loss attributable to:" } } }, "localname": "ProfitLossAttributableToAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to owners of parent", "terseLabel": "Owners of the parent" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r185", "r203", "r204" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "totalLabel": "Loss before taxes" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r43", "r81" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Loss from operations" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r15", "r58" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedTerseLabel": "Payment for purchase of intangible assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedTerseLabel": "Payment for purchase of property, plant and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r154", "r156", "r157", "r178", "r198", "r209" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]", "terseLabel": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r154", "r156", "r157", "r178", "r198", "r209" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]", "terseLabel": "Ranges" } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RawMaterials": { "auth_ref": [ "r28", "r63" ], "calculation": { "http://adctherapeutics.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "ifrs-full_InventoriesTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current raw materials", "terseLabel": "Current raw materials" } } }, "localname": "RawMaterials", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RelatedPartiesMember": { "auth_ref": [ "r74" ], "lang": { "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Joint ventures [member]; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Related parties [member]", "terseLabel": "Related parties" } } }, "localname": "RelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r100" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 2.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedTerseLabel": "Research and development expenses", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "auth_ref": [ "r66" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Cumulative translation adjustments" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r10", "r66" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Cumulative Translation Adjustments" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r29", "r47" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated losses" } } }, "localname": "RetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r9", "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Accumulated Losses" } } }, "localname": "RetainedEarningsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r158", "r159" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss": { "auth_ref": [ "r86", "r89" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of reversal of impairment loss recognised in profit or loss. [Refer: Reversal of impairment loss; Profit (loss)]" } }, "en-us": { "role": { "label": "Reversal of impairment loss recognised in profit or loss", "terseLabel": "Reversal of impairment loss recognised in profit or loss" } } }, "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r165" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets", "periodEndLabel": "Right-of-use asset, ending balance", "periodStartLabel": "Right-of-use asset, beginning balance", "terseLabel": "Right-of-use assets" } } }, "localname": "RightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet", "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SaleOrIssueOfTreasuryShares": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Sale or issue of treasury shares", "terseLabel": "Sale or issue of treasury shares" } } }, "localname": "SaleOrIssueOfTreasuryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SalesAndMarketingExpense": { "auth_ref": [ "r43" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": { "order": 3.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } }, "en-us": { "role": { "label": "Sales and marketing expense", "negatedTerseLabel": "Selling and marketing expenses", "terseLabel": "Sales and marketing expense" } } }, "localname": "SalesAndMarketingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod": { "auth_ref": [ "r43" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Share of profit (loss) of joint ventures accounted for using equity method", "negatedTerseLabel": "Share of results in joint venture", "terseLabel": "Share of results with joint venture" } } }, "localname": "ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows", "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r29" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium", "terseLabel": "Share premium" } } }, "localname": "SharePremium", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium [member]", "terseLabel": "Share Premium" } } }, "localname": "SharePremiumMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity", "http://adctherapeutics.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Share-based payment arrangements [member]", "terseLabel": "Share-based payment arrangements" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": { "auth_ref": [ "r31" ], "lang": { "en": { "role": { "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares." } }, "en-us": { "role": { "label": "Number of shares reserved for issue under options and contracts for sale of shares", "terseLabel": "Number of shares reserved for issue under options and contracts for sale of shares" } } }, "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_SignificantUnobservableInputLiabilities": { "auth_ref": [ "r149" ], "lang": { "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } }, "en-us": { "role": { "label": "Significant unobservable input, liabilities", "terseLabel": "Key inputs for valuations" } } }, "localname": "SignificantUnobservableInputLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]", "terseLabel": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfIFRSCompliance": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs." } }, "en-us": { "role": { "label": "Statement of IFRS compliance [text block]", "terseLabel": "Statement of Compliance" } } }, "localname": "StatementOfIFRSCompliance", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r154", "r156", "r157", "r178", "r198", "r209" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Top of range" } } }, "localname": "TopOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r20" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Accounts payable" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r18", "r27" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Accounts receivable, net" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasuryShares": { "auth_ref": [ "r29", "r80" ], "calculation": { "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury shares", "negatedTerseLabel": "Treasury shares" } } }, "localname": "TreasuryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasurySharesMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury shares [member]", "terseLabel": "Treasury Shares" } } }, "localname": "TreasurySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfInterestRatesAxis": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of interest rates [axis]", "terseLabel": "Types of interest rates [axis]" } } }, "localname": "TypesOfInterestRatesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r186", "r189", "r190", "r210", "r211", "r212", "r214" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]", "terseLabel": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/FinancialriskmanagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r186", "r189", "r190", "r210", "r211", "r212", "r214" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]", "terseLabel": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/FinancialriskmanagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]", "terseLabel": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails", "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsAxis": { "auth_ref": [ "r149", "r151" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Unobservable inputs [axis]", "terseLabel": "Unobservable inputs [axis]" } } }, "localname": "UnobservableInputsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsMember": { "auth_ref": [ "r149", "r151" ], "lang": { "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } }, "en-us": { "role": { "label": "Unobservable inputs [member]", "terseLabel": "Unobservable inputs" } } }, "localname": "UnobservableInputsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r91" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, intangible assets other than goodwill", "terseLabel": "Useful life measured as period of time, intangible assets other than goodwill" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_VehiclesMember": { "auth_ref": [ "r55" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Vehicles [member]", "terseLabel": "Vehicles" } } }, "localname": "VehiclesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails", "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Average strike price in USD per share, Exercised (in USD per share)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options expired in share-based payment arrangement", "terseLabel": "Average strike price in USD per share, Expired (in USD per share)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement", "terseLabel": "Average strike price in USD per share, Forfeited (in USD per share)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "terseLabel": "Fair value grant date (in USD per share)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r171", "r176" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Average strike price in USD per share, At end of the year (in USD per share)", "periodStartLabel": "Average strike price in USD per share, At beginning of the year (in USD per share)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r178" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Weighted average remaining contractual life of outstanding share options" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price, share options granted", "terseLabel": "Weighted average share price (in USD per share)" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r84" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of ordinary shares outstanding" } } }, "localname": "WeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/LosspershareDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_WorkInProgress": { "auth_ref": [ "r28", "r63" ], "calculation": { "http://adctherapeutics.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "ifrs-full_InventoriesTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]" } }, "en-us": { "role": { "label": "Current work in progress", "terseLabel": "Current work in progress" } } }, "localname": "WorkInProgress", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WrittenPutOptionsMember": { "auth_ref": [ "r199", "r200" ], "lang": { "en": { "role": { "documentation": "This member stands for derivative financial contracts sold that oblige the entity to purchase an underlying asset at a specified strike price if the other party exercises the option. [Refer: Derivatives [member]]" } }, "en-us": { "role": { "label": "Written put options [member]", "terseLabel": "Written put options (in USD per share)" } } }, "localname": "WrittenPutOptionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" ], "xbrltype": "domainItemType" }, "srt_CondensedIncomeStatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Income Statement [Table]", "terseLabel": "Condensed Income Statement [Table]" } } }, "localname": "CondensedIncomeStatementTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "stringItemType" }, "srt_CondensedIncomeStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Income Statements, Captions [Line Items]", "terseLabel": "Condensed Income Statements, Captions [Line Items]" } } }, "localname": "CondensedIncomeStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails", "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations", "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails", "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails", "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24" }, "r1": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24" }, "r10": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24" }, "r100": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24" }, "r101": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI", "URIDate": "2022-03-24" }, "r102": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard", "URIDate": "2022-03-24" }, "r103": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24" }, "r104": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2022-03-24" }, "r105": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24" }, "r106": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24" }, "r107": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24" }, "r108": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2022-03-24" }, "r109": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2022-03-24" }, "r11": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24" }, "r110": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24" }, "r111": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2022-03-24" }, "r112": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24" }, "r113": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24" }, "r114": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24" }, "r115": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2022-03-24" }, "r116": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24" }, "r117": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2022-03-24" }, "r118": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24" }, "r119": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24" }, "r12": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard", "URIDate": "2022-03-24" }, "r120": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24" }, "r121": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24" }, "r122": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24" }, "r123": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r124": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24" }, "r125": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2022-03-24" }, "r126": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24" }, "r127": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24" }, "r128": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24" }, "r129": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r13": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24" }, "r130": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r131": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r132": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "2", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r133": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "2", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_2_b_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r134": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "23", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_23_b&doctype=Standard", "URIDate": "2022-03-24" }, "r135": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r136": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r137": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r138": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r139": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r14": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51&doctype=Standard", "URIDate": "2022-03-24" }, "r140": { "Clause": "ix", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r141": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r142": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r143": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r144": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B14", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B14_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r145": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r146": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r147": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24" }, "r148": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24" }, "r149": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2022-03-24" }, "r15": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24" }, "r150": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24" }, "r151": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2022-03-24" }, "r152": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard", "URIDate": "2022-03-24" }, "r153": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24" }, "r154": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r155": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r156": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r157": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24" }, "r158": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2022-03-24" }, "r159": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard", "URIDate": "2022-03-24" }, "r16": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2022-03-24" }, "r160": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24" }, "r161": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2022-03-24" }, "r162": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2022-03-24" }, "r163": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2022-03-24" }, "r164": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2022-03-24" }, "r165": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2022-03-24" }, "r166": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24" }, "r167": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI", "URIDate": "2022-03-24" }, "r168": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI", "URIDate": "2022-03-24" }, "r169": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard", "URIDate": "2022-03-24" }, "r17": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2022-03-24" }, "r170": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2022-03-24" }, "r171": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r172": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r173": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r174": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2022-03-24" }, "r175": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2022-03-24" }, "r176": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2022-03-24" }, "r177": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2022-03-24" }, "r178": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24" }, "r179": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r18": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2022-03-24" }, "r180": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r181": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2022-03-24" }, "r182": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24" }, "r183": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "IG23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r184": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r185": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r186": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2022-03-24" }, "r187": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "24G", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24G_a&doctype=Standard", "URIDate": "2022-03-24" }, "r188": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24" }, "r189": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24" }, "r19": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24" }, "r190": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24" }, "r191": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24" }, "r192": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24" }, "r193": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2022-03-24" }, "r194": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24" }, "r195": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24" }, "r196": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard", "URIDate": "2022-03-24" }, "r197": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard", "URIDate": "2022-03-24" }, "r198": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r199": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r2": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24" }, "r20": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2022-03-24" }, "r200": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r201": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI", "URIDate": "2022-03-24" }, "r202": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24" }, "r203": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24" }, "r204": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24" }, "r205": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24" }, "r206": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2022-03-24" }, "r207": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Effective 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24" }, "r208": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24" }, "r209": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24" }, "r21": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2022-03-24" }, "r210": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard", "URIDate": "2022-03-24" }, "r211": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard", "URIDate": "2022-03-24" }, "r212": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24" }, "r213": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r214": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2022-03-24" }, "r215": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24" }, "r216": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard", "URIDate": "2022-03-24" }, "r217": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24" }, "r218": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24" }, "r219": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39J", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r22": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24" }, "r220": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r221": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r222": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r223": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r23": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24" }, "r24": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard", "URIDate": "2022-03-24" }, "r25": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24" }, "r26": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r27": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24" }, "r28": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2022-03-24" }, "r29": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24" }, "r3": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24" }, "r30": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r31": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_vii&doctype=Standard", "URIDate": "2022-03-24" }, "r32": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24" }, "r33": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2022-03-24" }, "r34": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24" }, "r35": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24" }, "r36": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2022-03-24" }, "r37": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24" }, "r38": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r39": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r4": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24" }, "r40": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24" }, "r41": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24" }, "r42": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2022-03-24" }, "r43": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24" }, "r44": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24" }, "r45": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2022-03-24" }, "r46": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24" }, "r47": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r48": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24" }, "r49": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI", "URIDate": "2022-03-24" }, "r5": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24" }, "r50": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24" }, "r51": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24" }, "r52": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r53": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2022-03-24" }, "r54": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81&doctype=Standard", "URIDate": "2022-03-24" }, "r55": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24" }, "r56": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24" }, "r57": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2022-03-24" }, "r58": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24" }, "r59": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2022-03-24" }, "r6": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r60": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2022-03-24" }, "r61": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2022-03-24" }, "r62": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2022-03-24" }, "r63": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24" }, "r64": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI", "URIDate": "2022-03-24" }, "r65": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24" }, "r66": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2022-03-24" }, "r67": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24" }, "r68": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24" }, "r69": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2022-03-24" }, "r7": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r70": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24" }, "r71": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24" }, "r72": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24" }, "r73": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard", "URIDate": "2022-03-24" }, "r74": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24" }, "r75": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24" }, "r76": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI", "URIDate": "2022-03-24" }, "r77": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24" }, "r78": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24" }, "r79": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24" }, "r8": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24" }, "r80": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24" }, "r81": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r82": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24" }, "r83": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24" }, "r84": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24" }, "r85": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI", "URIDate": "2022-03-24" }, "r86": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "126", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126_b&doctype=Standard", "URIDate": "2022-03-24" }, "r87": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24" }, "r88": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24" }, "r89": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "129", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_129_b&doctype=Standard", "URIDate": "2022-03-24" }, "r9": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24" }, "r90": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r91": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2022-03-24" }, "r92": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24" }, "r93": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2022-03-24" }, "r94": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2022-03-24" }, "r95": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2022-03-24" }, "r96": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24" }, "r97": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24" }, "r98": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2022-03-24" }, "r99": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard", "URIDate": "2022-03-24" } }, "version": "2.1" }